

CTAD 2026

MONDAY, NOVEMBER 16

2:15 – 3:15 pm	POSTER WALKING TOUR
3:15 – 3:25 pm	<p>Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research presented to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.</p> <p><i>Introduction by the CTAD Organizing Committee</i></p> <p>Reisa Sperling, Brigham and Women's Hospital Harvard Medical School - Boston (United States)</p> <p>Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)</p> <p>Sandrine Andrieu, Toulouse University Hospital and INSERM 1295, Toulouse (France)</p> <p>Jacques Touchon, Montpellier University, Montpellier (France)</p> <p>Bruno Vellas, IHU HealthAge, Toulouse University, Toulouse (France)</p> <p>Mike Weiner, UCSF, San Francisco, CA (United States)</p>
3:25 – 3:50 pm	<p>KEYNOTE 1</p> <p>New Molecules in Phase 2b – Proof of Concept and Beyond</p> <p>Jeffrey Cummings University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)</p> <p><i>Introduction: Bruno Vellas, IHU HealthAge, Toulouse University, Toulouse (France)</i></p>
3:50 – 4:50 pm	<p>ORAL COMMUNICATIONS</p> <p>OC1 Top-Line Results of SINGER: A Two-Year Randomized Controlled Trial of Multidomain Lifestyle Intervention to Prevent Cognitive Decline</p> <p>Kwong Hsia Yap¹, Liang Shen², David Matchar^{3,4}, Helen Zhou^{5,6}, Mitchell Kim Peng Lai⁷, Xin Xu⁸, Cynthia Huijun Chen⁹, Laura Baker¹⁰, Miia Kivipelto^{11,12,13}, Nagaendran Kandiah¹⁴, Christopher Chen^{1,7}</p> <p><i>¹Memory, Ageing and Cognition Centre (MACC), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ²Singapore Clinical Research Institute - Singapore (Singapore), ³Health Services and Systems Research Programme, Duke-NUS Medical School - Singapore (Singapore), ⁴Division of General Internal Medicine, Department of Medicine, Duke University, Durham - North Carolina (United States), ⁵Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁶Department of Electrical and Computer Engineering, National University of Singapore, - Singapore (Singapore), ⁷Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁸School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, - Zhejiang (China), ⁹Saw Swee Hock School of Public Health, National University of Singapore - Singapore (Singapore), ¹⁰Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem - North Carolina (United States), ¹¹Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, - Stockholm (Sweden), ¹²Ageing Epidemiology Research Unit, School of Public Health, Imperial College London - London (United Kingdom), ¹³Institute of Public Health and Clinical Nutrition, University of Eastern Finland - Kuopio (Finland), ¹⁴Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University - Singapore (Singapore)</i></p> <p>OC2 POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer's Disease: Efficacy Outcomes at 52 Weeks and Safety Through the Extension Phase</p>

[Sharon Sha](#)¹, [Alireza Atri](#)², [Fernando Melgar-Somoza](#)³, [Marzena Zboch](#)⁴, [Do Hoon Kim](#)⁵, [Yi Tang](#)⁶, [Jennifer Lynch](#)⁷, [Howard Chertkow](#)⁸, [Sangyun Kim](#)⁹, [David Greeley](#)¹⁰, [James Rock](#)¹¹, [Fred Kim](#)¹¹, [Tianyang Xi](#)¹¹, [Jai Jun Choung](#)¹¹

¹Stanford - Palo Alto (United States), ²Banner Sun Health Research and Banner Alzheimer's Institutes - Sun City (United States), ³Melgar-Caro MedCenter and Community Research - Miami (United States), ⁴Wroclawskie Centrum Alzheimerowski - Wroclaw (Poland), ⁵Chuncheon Sacred Heart Hospital - Chuncheon (Korea, Republic of), ⁶Xuanwu Hospital Capital Medical University - Beijing (China), ⁷Glasgow NeuroClin - Motherwell (United Kingdom), ⁸Baycrest Centre for Geriatric Care - Ontario (Canada), ⁹Seoul National University College of Medicine - Seoul (Korea, Republic of), ¹⁰Northwest Neurological - Spokane (United States), ¹¹Aribio Co., Ltd - San Diego (United States)

OC3 Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification

[Alpana Singh](#)¹, [Marisa Denkinger](#)¹, [Geidy E. Serrano](#)¹, [Thomas G. Beach](#)¹, [Eric M. Reiman](#)², [Shorena Janelidze](#)³, [Oskar Hansson](#)³, [Niklas Mattsson-Carlgrén](#)³, [Pedro Rosa Neto](#)⁴, [Nicholas Ashton](#)¹

¹Banner Sun Health Research Institute - Sun City (United States), ²Banner Alzheimer's Institute - Phoenix (United States), ³Lund University - Lund (Sweden), ⁴UT Southwestern Medical Center - Austin (United States)

OC4 Plasma p-tau217 outperforms neuroimaging biomarkers in predicting the risk of cognitive impairment in a multi-cohort study

[Colin Birkenbihl](#)¹, [Madison Cuppels](#)¹, [Diana Townsend](#)¹, [Gillian Coughlan](#)¹, [Mabel Seto](#)¹, [Jane Brown](#)¹, [Michael Properzi](#)¹, [Annie Li](#)¹, [Bryan James](#)², [Robert Rissman](#)³, [Melissa Petersen](#)⁴, [Tobey Betthausen](#)⁵, [Doreen Rentz](#)¹, [Reisa Sperling](#)¹, [Rachel Buckley](#)¹

¹Mass General Brigham - Boston (United States), ²Rush Alzheimer's Disease Center - Chicago (United States), ³University of Southern California - Los Angeles (United States), ⁴University of North Texas - Fort Worth (United States), ⁵University of Wisconsin-Madison - Madison (United States)

4:50 – 5:30 pm

SYMPOSIUM 1

Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab

Chair: [Tammie L.S. Benzinger](#), Washington University in St. Louis -St. Louis, Missouri, (United States)

Presentation 1 Brain delivery and distribution of the novel Brainshuttle™ Aβ-targeting antibody trontinemab in participants with Alzheimer's disease measured with ⁸⁹Zr positron emission tomography

[Elsmarieke Van De Giessen](#), Amsterdam UMC, Vrije Universiteit - Amsterdam (The Netherlands)

Presentation 2 Trontinemab in Alzheimer's disease – novel pharmacodynamic insights from the ongoing Phase Ib/IIa Brainshuttle™ AD study

[Luka Kulic](#), F. Hoffmann-La Roche Ltd - Basel (Switzerland)

Presentation 3 Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer's disease

[Gregory Klein](#), F. Hoffmann-La Roche Ltd - Basel (Switzerland)

5:30 – 6:15pm

LATE BREAKING

Late Breaking Communications

6:15 – 7:15pm

CTAD Welcome Reception with the Support of the Alzheimer's Association

7:30 – 8:30 am

POSTER WALKING TOUR

8:30– 09:10 am

SYMPOSIUM 2

When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes

Chair: Fiona Elwood, Johnson & Johnson, Cambridge, MA, USA

Presentation 1 Spatial Determinants of Posdinemab's Effect on Tau PET

Ziad S. Saad, Johnson & Johnson, San Diego, CA (United States)

Presentation 2 CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial

Gallen Triana-Baltzer, Johnson & Johnson, San Diego, CA (United States)

Presentation 3 Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial

Gil D. Rabinovici, University of California, San Francisco (UCSF) - San Francisco, CA (United States)

9:10– 9:35 am

KEYNOTE 2

A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)

Introduction Reisa Sperling, Brigham and Women's Hospital Harvard Medical School - Boston (United States)

9:35 – 10:35 am

ORAL COMMUNICATIONS

OC05 Efficacy and Safety of Remlifanserin in Patients With Alzheimer's Disease Psychosis

Sanjeev Pathak¹, Clive Ballard², Jeffrey Cummings³, Samantha Friend⁴, Becky Howell¹, Christine Murphy⁴, Xiaoshu Feng¹, Mona Darwish¹, Bryan Dirks¹

¹Acadia Pharmaceuticals Inc. - Princeton (United States), ²University of Exeter Medical School - Exeter (United Kingdom), ³Kirk Kerkorian School of Medicine, University of Nevada - Las Vegas (United States), ⁴Acadia Pharmaceuticals Inc. - San Diego (United States)

OC06 Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies

Lon Schneider¹, Guoqiao Wang², Richard Kennedy³, Gary Cutter³, Robert Howard⁴

¹USC Keck School of Medicine - Los Angeles (United States), ²Washington University in St. Louis - St. Louis (United States), ³University of Alabama, Birmingham - Birmingham (United States), ⁴University College London - London (United Kingdom)

OC07 Topline results from the Phase 2b PRImus-AD trial: Safety and efficacy of oral PRI-002 in early AD

Oliver Peters^{1,2}, Dagmar Jürgens^{2,3}, Gerhard Tischler³, Tina Bartsch³, Lorenzo Bulli³, Katja Lindner³, Julie-Anne Gabelich³, Julia Post-Schulz³, Gunther Kauselmann^{2, 3}, Knut Adermann^{2, 3}, Kathrin Zeiger³, Alexander Brener³, Dieter Willbold^{2,4}

¹Charité - Universitätsmedizin Berlin - Berlin (Germany), ²Priavoid - Düsseldorf (Germany), ³PRInnovation - Düsseldorf (Germany), ⁴Institut für Pysikalische Biologie, Heinrich-Heine Universität Düsseldorf - Düsseldorf (Germany)

OC08 Sex Differences in Plasma p-tau217, Amyloid-β, and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort

[Gillian Coughlan](#)¹, Madison Cuppels¹, Aaron Schultz¹, Keith Johnson¹, Robert Rissman², Doris Molina-Henry², Michael Donohue², Oliver Longford², Paul Aisen², Joel Braunstein³, Michael Irizarry⁴, Shobha Dhadda⁴, Rachel Buckley¹, Reisa Sperling¹, Ahead 3-45 Study Team⁵

¹Mass General Brigham, Department of Neurology - Boston (United States), ²University of Southern California Alzheimer Therapeutic Research Institute - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴EISAI - Nutley (United States), ⁵University of Southern California, Alzheimer Clinical Trials Consortium - San Diego (United States)

10:35 – 11:05 am

Coffee break - poster session and Rising Star Showcase

11:05 – 11:45 am

SYMPOSIUM 3

Remote Digital Biomarkers in Alzheimer's Disease Clinical Trials: From Scalable Prescreening to Sensitive AI-Enabled Assessment

Co-chairs: [Gustavo A. Jimenez-Maggiara](#), Alzheimer's Therapeutic Research Institute (ATRI), Epstein Family Center for Alzheimer's Disease Research, Keck School of Medicine of USC, San Diego, CA – (United States)
[Duygu Tosun](#),— University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 1 The voice Clinical Dementia Rating® (vCDR) to facilitate clinical assessment for dementia research and trials using a generative AI powered conversational agent [Rachel L. Nosheny](#), University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 2 Using digital multi-day learning curves for scalable early detection and tracking of subtle cognitive decline in preclinical AD

[Kathryn V. Papp](#), Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Massachusetts General Hospital; Harvard Medical School -Boston, MA (United States)

Presentation 3 Real world feasibility, utility and generalizability of self-administered speech-based testing for scalable pre-screening for Mild Cognitive Impairment: results from the full ADNI4 digital cohort

[Emil Fristed](#), Novoic Ltd.; Coagen Limited – London (United Kingdom)

11:45 – 12:20 pm

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

BIOTECH SHOWCASE 1 Phase 2a AD Trial Results: NTRX-07 Reduces Neuroinflammation and Inhibits Neurodegeneration Following 28-days of Treatment

[Joseph Foss](#)¹, [Marianna Kiraly](#)¹, [Peter Kovacs](#)², [Tony Giordano](#)¹

¹NeuroTherapia, Inc. - Cleveland (United States), ²CRU Global - Budapest (Hungary)

BIOTECH SHOWCASE 2 A Next-Generation circRNA Blood Biomarker Platform for Alzheimer's Disease Detection, Progression Prediction, and Clinical Deployment

[Nikolaos Mellios](#)¹, [Bridget Phillips](#)², [Sanford Jessie](#)², [Janve Vaibhav](#)³, [Papageorgiou Grigoris](#)³, [Morris John](#)², [Perlmutter Joel](#)², [Kotzbauer Paul](#)², [Perrin Richard](#)², [Hohman Timothy](#)³, [Ibanez Laura](#)², [Cruchaga Carlos](#)²

¹Circular Genomics - San Diego (United States), ²Washington University School of Medicine - St. Louis (United States), ³Vanderbilt University Medical Center - Nashville (United States)

BIOTECH SHOWCASE 3 Sinaptica Therapeutics, Inc. ~ Precuneus-directed TMS-EEG precision-neuromodulation platform

[Giacomo Koch](#)¹

¹Sinaptica Therapeutics - Cambridge (United States)

12:20 – 1:35 pm

Lunch and poster sessions

1:35 - 2:35 pm

ORAL COMMUNICATIONS

OC09 A Unified Timeline of Alzheimer's Disease: Linking Amyloid-β to Cognitive Decline

Rosita Shishegar¹, Timothy Cox², Marcela Cespedes³, Suzanne Schindler⁴, Tammie Benzinger⁵, Christopher C Rowe⁶, Christopher J Fowler⁷, Stephanie R Rainey-Smith^{8, 9, 10}, Simon Laws¹¹, Mike Weiner¹², John Morris⁴, Colin L Masters¹³, Hamid Sohrabi¹⁴, Paul Maruff¹⁵, James D Doecke^{3, 11}

¹The Australian e-Health Research Centre, CSIRO - Parkville (Australia), ²The Australian e-Health Research Centre, CSIRO - Canberra (Australia), ³The Australian e-Health Research Centre, CSIRO - Herston (Australia), ⁴Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁵Washington University School of Medicine - St Louis (United States), ⁶Austin Health - Heidelberg (Australia), ⁷The Florey Institute, The University of Melbourne - Parkville (Australia), ⁸Australian Alzheimer's Research Foundation - Perth (Australia), ⁹Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup, ¹⁰Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch, ¹¹Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ¹²University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Medical Center - San Francisco (United States), ¹³Alzheimer's Research Australia, University of Western Australia - Perth (Australia), ¹⁴Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch (Australia), ¹⁵Cogstate Ltd. - Parville (Australia)

OC10 When Plasma ptau217 and AβPET Disagree: Factors Associated With Biomarker Concordance and Discordance Across Ethnoracial Groups

Mahnaz Shekari¹, Tessa Harrison¹, Yishu Chao¹, Robert Rissman², Sid O'bryant³, Petersen Melissa⁴, William J Jagust¹, Susan M Landau¹

¹University of California - Berkeley (United States), ²University of California - San Diego (United States), ³University of North Texas Health Science Center - Texas (United States), ⁴Institute for Translational Research, University of North Texas Health Science Center - Texas (United States)

OC11 Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice

Dickson Samuel¹, John Whetten¹, Chenge Zhang¹, Suzanne Hendrix¹, Katherine Youmans-Kidder², Daryl Jones²

¹Pentara Corporation - Salt Lake City (United States), ²Eisai Inc. - Nutley (United States)

OC12 Detecting cognitive decline in preclinical AD over 1.5 years using digital cognitive assessments.

Hairin Kim¹, Mark Dubbelman¹, Lex Minto¹, Daniel Soberanes¹, Vivienne Lubbat¹, Dorene Rentz¹, Gad Marshall¹, Reisa Sperling¹, Laura Baker², Mark Espeland², Susan Landau³, Rebecca Amariglio¹, Kathryn Papp¹

¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Department of Internal Medicine, Wake Forest University School of Medicine - Winston-Salem (United States), ³Helen Wills Neuroscience Institute (SL), University of California - Berkeley (United States)

2:35 – 3:15 pm

SYMPOSIUM 4

Neuroinflammation in Alzheimer's Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk

Chair: Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 1 Central-Peripheral Neuroimmune Crosstalk: Targeting Immune Dysfunction to Reduce Neurodegenerative Disease Progression

Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 2 NLRP3 regulates microglial immune and metabolic function in dementia

Róisín M. McManus, German Center for Neurodegenerative Diseases (DZNE), Venusberg Campus - Bonn (Germany)

Presentation 3 The NLRP3 inflammasome as a therapeutic target in Alzheimer's disease: biomarker, preclinical evidence and Phase I healthy participants' safety data of the oral inhibitor RG6434

Gennaro Pagano, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

3:15 – 4:15 pm

ORAL COMMUNICATIONS

OC13 Treatment with Pepinemab, Anti-SEMA4D Blocking Antibody, Reduces a Unique Astrocyte Subset (Ast10) Correlated with Cognitive Decline and Associated Biomarkers of Synaptic Loss in People with Early-Stage AD

Elizabeth Evans¹, Terrence Fisher¹, Leslie Balch¹, Natacha Comandante-Lou², Vikas Mishra¹, John Leonard¹, Loretta Mueller¹, Alan Howell¹, Charlotte E Teunissen³, Lisa Vermunt³, Anton Porsteinsson⁴, Hyun Keun Cho⁵, Howard H Feldman⁵, Lon Scheider⁶, Maurice Zauderer¹

¹Vaccinex, Inc - Rochester (United States), ²Columbia University Irving Medical Center - New York (United States), ³Amsterdam UMC - Amsterdam (The Netherlands), ⁴University of Rochester, *on behalf of SIGNAL-AD investigators - Rochester (United States), ⁵University of California, San Diego - San Diego (United States), ⁶University of Southern California, Keck School of Medicine - Los Angeles (United States)

OC14 Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer's Disease

Nicolas R Barthelemy¹, Soumya Mukherjee¹, Yingxin He¹, Vitaliy Ovod¹, Kanta Horie¹, Rama Koppiseti¹, Ani Eloyan², Dustin B Hammers³, Kelly N Nudelman³, Maria C. Carrillo⁴, Bradford C. Dickerson⁵, Gil D Rabinovici⁶, Liana G Apostolova³, Randall J Bateman¹, Jeffrey L. Dage¹

¹Washington University - St. Louis (United States), ²Brown University - Providence (United States), ³Indiana University - Indianapolis (United States), ⁴Alzheimer's Association - Chicago (United States), ⁵Harvard Medical School - Charlestown (United States), ⁶UCSF - San Francisco (United States)

OC15 Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts

Richard Haarbuerger¹, James Mbinta², Siu Yuat Wong¹, Alex Wang², Colin Simpson³, Noah Stegehuis¹, Till Baernighausen⁴, Greg Martin⁵, Yoram Barak⁶, Andrew Sporle³, Aliitasi Su'a-Tavalla², Pascal Geldsetzer¹

¹Stanford University - Stanford (United States), ²Victoria University - Wellington (New Zealand), ³University of Auckland - Auckland (New Zealand), ⁴Heidelberg University - Heidelberg (Germany), ⁵New Zealand Ministry of Health - Wellington (New Zealand), ⁶Dunedin School of Medicine - Dunedin (New Zealand)

OC16 Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study

Adrian Noriega De La Colina^{1,2,3}, Arvid Gollwitzer^{1,2}, Anna Matton^{4,5,6}, Francesca Mangialasche^{7,5,6}, Li-Huei Tsai^{1,8}, Alina Solomon^{6,4,9}, Tiia Ngandu^{6,9}, Giovanni Traverso^{1,2,3,10}, Miia Kivipelto^{4,5,11}

¹Broad Institute of MIT and Harvard - Cambridge (United States), ²Massachusetts Institute of Technology - Cambridge (United States), ³Brigham and Women's Hospital - Boston (United States), ⁴Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁵Division of Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁶FINGERS Brain Health Institute - Stockholm (Sweden), ⁷Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden) - Solna (Sweden), ⁸The Picower Institute for Learning and Memory - Cambridge (United States), ⁹Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), ¹⁰Koch Institute for Integrative Cancer Research, MIT - Cambridge (United States), ¹¹FINGERS Brain Health Institute - Stockholm (Sweden)

4:15 – 4:45pm

Coffee break - poster session and Rising Star Showcase

4:45 – 5:25pm

SYMPOSIUM
LATE BREAKING SYMPOSIUM 1

7:30 – 8:30 am	POSTER WALKING TOUR
8:30 – 09:30 am	<p>LATE BREAKING</p> <p>Late Breaking Communications</p>
9:30 – 9:55 am	<p>KEYNOTE 3</p> <p>Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics</p> <p>Susan Landau, PhD, Research Neuroscientist, Helen Wills Neuroscience Institute University of California, Berkeley, CA (United States)</p> <p><i>Introduction : Michael Weiner, University of California, San Francisco – San Francisco, CA (United States)</i></p>
09:55 – 10 :35 am	<p>ORAL COMMUNICATIONS</p> <p><i>Session on Study Design and Phase 1/Phase 2a Studies</i></p> <p>OC17 PreventRON: Evaluating the effect of trolinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline</p> <p><u>Reisa Sperling</u>¹, Catherine Mummery², Jeffrey L. Cummings³, Gil Rabinovici⁴, Stephen Salloway⁵, Henrik Zetterberg⁶, Juan Fortea⁷, Frank G. Boess⁸, Christopher Lane⁹, Marion Monchalin⁸, Paul Delmar⁸, Luka Kulic⁸, Hanno Svoboda⁸, Geoffrey A. Kerchner⁸, Janice Smith⁹</p> <p>¹Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Queen Square Institute of Neurology, University College London - London (United Kingdom), ³Chambers-Grundy Center for Transformative Neuroscience, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), ⁴Weill Institute for Neurosciences, Department of Radiology and Biomedical Imaging, University of California San Francisco - San Francisco (United States), ⁵Warren Alpert Medical School, Brown University - Providence (United States), ⁶Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), ⁷Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Antoni Maria Claret - Barcelona (Spain), ⁸F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁹Roche Products Ltd - Welwyn Garden City (United Kingdom)</p> <p>OC18 A Prospective, Observational, Fully Decentralized Global Study to Identify Individuals for Alzheimer’s Disease Clinical Trials Using Digital Cognitive Assessments and Blood-Based Biomarkers</p> <p><u>Jennifer Murphy</u>¹, Joaquin Penalver De Andres², Josh Guo², Katie King², Richard Haslop², Matt Gifford², Luis Castelo Branco², Carrie Rubel², Peggy Kennedy², Ellen Huang², David Clifford²</p> <p>¹Biogen - San Francisco, CA (United States), ²Biogen – Cambridge, MA (United States)</p> <p>OC19 Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer’s Disease; a First-in-Human Study</p> <p><u>Christopher Duma</u>¹, Jessica Buxton², Hans Keirstead³, Gabriel Nistor², Robert Lynn², Sawyer Farmer², Ashley Harris², Karlyssa Chung², Nathaniel Cho², Zoe Hareng², Jason Bock², Benjamin Rapaport², Gustavo Alva¹</p> <p>¹Hoag Memorial Hospital - Newport Beach, CA (United States), ²Regeneration Biomedical, Inc. - Newport Beach, CA (United States), ³Aivita Biomedical, Inc. – Irvine, CA (United States)</p> <p>OC20 A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer’s disease: Study rationale and design</p> <p><u>W. Joseph Herring</u>¹, Yuchuan Wang¹, Li He¹, Yuki Mukai¹, Christine Furtek¹, Angela Gee¹, Andrei Popescu¹, Seth Robey¹, Michael F. Egan¹</p> <p>¹Merck & Co., Inc. – Rahway, NJ (United States)</p>
10:35 – 11:05 am	Coffee break - poster session and Rising Star Showcase

11:05 – 11:25 am

BIOTECH SHOWCASE

Biotech Showcase session

BIOTECH SHOWCASE 4 00066 A First-in-Class CNS-Penetrant Small Molecule Targeting APOE4-mediated Neurovascular Dysfunction in Alzheimer's Disease

Caghan Kizil¹, Badri Vardarajan¹, Richard Mayeux¹

¹Department of Neurology, Columbia University Irving Medical Center - New York City (United States) Late breaking Biotech Showcase sessions

11:25 – 12:05pm

SYMPOSIUM 5

Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings

Chair: Marwan Sabbagh, Barrow Neurological Institute - Phoenix, AZ (United States)

Presentation 1 Real-World Lecanemab Utilization and Outcomes from Initiation Through Maintenance Therapy in Early Alzheimer's Disease: A Multicenter Retrospective Study (LEADER)

Jose Soria, The Neuron Clinic - Chula Vista, CA (United States)

Presentation 2 Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Multicenter, Real-World, Retrospective Study (LEADER)

Tinatin Chabrashvili, SUNY Upstate Medical University - New York, NY (United States)

Presentation 3 At-Home Subcutaneous Lecanemab Administration: A Multicenter, Real-World, Retrospective Study (LEADER) Brent Berry, Minneapolis Clinic of Neurology - Minneapolis, MN (United States)

12:05 – 12:50 pm

ORAL COMMUNICATIONS

OC21 Using Plasma P-tau217 and APOE Genotype to Predict Onset of Symptoms of Alzheimer's Disease

Yuexuan Xu¹, Tamil Gunasekaran¹, Yian Gu¹, Lawrence Honig¹, Jennifer Manly¹, Adam Brickman¹, Corinne Engelman², Sterling Johnson², David Bennett³, Sid O'bryant⁴, Caghan Kizil¹, Badri Vardarajan¹, Richard Mayeux¹

¹Columbia University - New York (United States), ²University of Wisconsin-Madison - Madison (United States), ³Rush University - Chicago (United States), ⁴University of North Texas Health Science Center - Fort Worth (United States)

OC22 AAV2-BDNF Gene Therapy in Alzheimer's Disease and Mild Cognitive Improvement Improves FDG-PET in Memory Circuitry

Yilong Ma¹, Gabriel Leger², Douglas Scharre³, Andrea Davis³, Kai Christman², Sara Rahman², Russell Lonser³, Krystopf Bankiewicz³, Eidelberg David¹, Bradley Elder³, Tuszynski Mark²

¹Feinstein Institute for Medical Research - Manhasset, NY (United States), ²UC San Diego - La Jolla, CA (United States), ³Ohio State University - Columbus, OH (United States)

OC23 Leveraging the Global Neurodegeneration Proteomics Consortium Dataset to Identify Plasma Proteomic Profiles Associated with Alzheimer's Disease Progression and Biological Endotypes

Jennifer Panlilio¹, Lydia Wu², Olga Kahn¹, Jennifer Hsiao-Nakamoto¹, Varsha Krish², Farhad Imam², Ilya Barshai³, Sergey Feldman³, Laura Nisenbaum⁴, Aishwarya Sukumar²

¹Diagnostics Accelerator, Alzheimer's Drug Discovery Foundation - New York (United States), ²Gates Ventures - Seattle (United States), ³Data Cowboys - Seattle (United States), ⁴Alzheimer's Drug Discovery Foundation - New York (United States)

12:50– 2:05 pm

Lunch and poster session

2:05– 2:40pm

LATE BREAKING

Late Breaking Communications

ORAL COMMUNICATIONS

OC24 Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score (Unirs)

Wagner S. Brum¹, Marisa N. Denkinger², Alpna Singh², Tainá Marques², Lennessa Mazo³, Rachael E. Wilson⁴, Ramiro Eduardo Rea Reyes⁴, Henrik Zetterberg⁵, Antoine Leuzy¹, Valentina Ghisays⁶, Reisa A. Sperling⁷, Eric M. Reiman⁶, Jessica B. Langbaum⁶, Sterling C. Johnson⁴, Nicholas J. Ashton⁶

¹ZRO Imaging - Santiago De Compostela (Spain), ²Banner Sun Health Research Institute - Sun City (United States), ³Arizona State University - Phoenix (United States), ⁴University of Wisconsin–Madison - Madison (United States), ⁵University of Gothenburg - Gothenburg (Sweden), ⁶Banner Alzheimer's Institute - Phoenix (United States), ⁷Harvard Medical School - Boston (United States)

OC25 Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer's disease: data from PET, MRI and CSF with long-term follow-up

Jonas E. Svensson¹, Ruben Dörfel¹, Martin Schain², Martin Bolin¹, Simona Sacuiu¹, Göran Hagman¹, Anton Forsberg Morén¹, Miia Kivipelto¹, Pontus Plavén-Sigra¹

¹Karolinska Institutet - Stockholm (Sweden), ²Antaros Medical - Mölndal (Sweden)

OC26 Longitudinal characterization of tau PET accumulation and spread anchored to amyloid and tau positivity timelines

Samira Maboudian¹, Karly Cody², William Coath¹, Julie Oomens¹, Jacob Morse¹, Hailey Bruzzone¹, Ramiro Rea Reyes¹, Matthew Zammit¹, Bradley Christian¹, Sanjay Asthana¹, Nathaniel Chin¹, Jessica Caldwell¹, Sterling Johnson¹, Tobey Betthausen¹

¹University of Wisconsin – Madison - Madison (United States), ²University of California San Francisco - San Francisco (United States)

OC27 Beyond amyloid and tau: Hippocampal volume and cognitive performance in the AHEAD-345 Study screening cohort

Benjamin Zide¹, Aaron Schultz¹, Michael Properzi¹, Michael Rafii², Gustavo Jimenez-Maggiora², Michael Donohue², Oliver Langford², Paul Aisen², Jin Zhou³, Michael Irizzary³, Shobha Dhadda³, Keith Johnson¹, Rachel Buckley¹, Reisa Sperling¹, . On Behalf Of The Ahead 3-45 Study Team⁴

¹Center for Alzheimer Research and Treatment, Mass General Brigham, Harvard Medical School - Boston, Ma (United States), ²Epstein Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), ³Eisai Inc. - Nutley, Nj (United States), ⁴AHEAD 3-45 Study Team, Alzheimer Clinical Trials Consortium (United States)

Coffee break - poster session and Rising Star Showcase

ORAL COMMUNICATIONS

OC28 Comparison of MK6240, Flortaucipir, PI2620 and RO948 tau PET tracers and plasma pTau217 across the Alzheimer's disease continuum

Guilherme Povala¹, Bruna Bellaver¹, Pamela C. L. Ferreira¹, Firoza Z. Lussier¹, Livia Amaral¹, Juan Fortea², Thomas K. Karikari¹, David N. Soleimani-Meigooni³, Val J. Lowe⁴, Hwamee Oh⁵, Brian A. Gordon⁶, Belen Pascual⁷, Pedro Rosa-Neto⁸, Suzanne Baker⁹, Tharick A. Pascoal¹

¹University of Pittsburgh, Department of Psychiatry - Pittsburgh (United States), ²Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ³University of California San Francisco, Edward and Pearl Fein Memory and Aging Center - San Francisco (United States), ⁴Mayo Clinic, Department of Radiology - Rochester (United States), ⁵Brown University, Department of Psychiatry and Human Behavior - Providence (United States), ⁶Washington University in St. Louis, Department of Radiology - St. Louis (United States), ⁷Houston Methodist Research Institute and Weill Cornell Medicine, Department of Neurology - Houston (United States), ⁸Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montréal (Canada), ⁹Lawrence Berkeley National Laboratory - Berkeley (United States)

OC29 Characterization of US Real-World Patients Receiving Donanemab with Modified Titration Using the NeuroDiscovery AI Database

Cara Leahy¹, Drew Spargo², Erin Gautier Doty², J. Scott Andrews², Krista Marie Schroeder², Vamsi Chandra Kasivajjala³, Akash Bhushan⁴, Anand Kumar Srirampurapu⁴, Ann Hart²

¹Memorial Healthcare Institute for Neuroscience - Owosso (United States), ²Eli Lilly and Company - Indianapolis (United States), ³NeuroDiscovery AI - Alpharetta (United States), ⁴NeuroDiscovery AI - Bangalore (India)

OC30 Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression

Menghan Liu¹, Katherine Gong¹, Yike Chen¹, Ying Xu¹, Jigyasha Timsina¹, John Budde¹, John Morris¹, Marco Giorgetti², David Holtzman¹, Jeremiah Hinson², Scott Levin², Suzanne Schindler¹, Kausik Das², Muhammad Ali¹, Carlos Cruchaga¹

¹Washington University School of Medicine - St. Louis, MO (United States), ²Danaher Diagnostics - Washington DC (United States)

7:30 – 8:30 am	<p>POSTER WALKING TOUR</p>
8:30 – 09:10 am	<p>SYMPOSIUM</p> <p>LATE BREAKING SYMPOSIUM 2</p>
09:10 – 10:10am	<p>ORAL COMMUNICATIONS</p> <p>OC31 Early versus delayed cognitive effects of donanemab and lecanemab in early Alzheimer’s disease: 24-month real-world trajectories and drug-specific baseline predictors of response <u>Yuki Kujuro</u>¹ ¹Tachikawa Hospital - Tokyo (Japan)</p> <p>OC32 CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progression Xuemei Zeng¹, Marissa F Farinas¹, Michel N Nafash¹, Neelesh Nadkarni¹, C. Elizabeth Shaaban¹, Tharick A Pascoal¹, Victor L Villemagne¹, Beth E Snitz¹, Milos D Ikonovic¹, Julia K Kofler¹, M. Ilyas Kamboh¹, Annie D Cohen¹, Oscar L Lopez¹, <u>Thomas K Karikari</u>¹ ¹University of Pittsburgh - Pittsburgh (United States)</p> <p>OC33 Understanding intermediate values in two-point thresholds for PET, CSF, and plasma biomarkers across cohorts and p-tau217 assays <u>Jacob Ziontz</u>¹, Ganna Blazhenets¹, Zoe Lin¹, John Kornack¹, Susan Landau², Leslie Shaw³, Jeffrey Dage⁴, Dustin Hammers⁴, Ani Eloyan⁵, Robert Koeppe⁶, Maria Carrillo⁷, Bradford Dickerson⁸, Liana Apostolova⁴, Gil Rabinovici¹, Renaud La Joie¹ ¹University of California, San Francisco - San Francisco, CA (United States), ²University of California, Berkeley - Berkeley, CA (United States), ³University of Pennsylvania – Philadelphia, PA (United States), ⁴Indiana University – Bloomington, IN (United States), ⁵Brown University – Providence, RI (United States), ⁶University of Michigan - Ann Arbor, MI (United States), ⁷Alzheimer’s Association – Chicago, IL (United States), ⁸Massachusetts General Hospital – Boston, MA (United States)</p> <p>OC34 Diagnostic Performance of the Fujirebio Lumipulse Plasma p-tau217 and p-tau217/Aβ42 Assays for Detection of Amyloid Pathology in Cognitively Unimpaired Individuals <u>Daniel Figdore</u>¹, Jeremy Syrjanen¹, Joshua Bornhorst¹, Jonathan Graff-Radford¹, Prashanthi Vemuri¹, David Knopman¹, Clifford Jack¹, Ronald Petersen¹, Alicia Algeciras-Schimmich¹ ¹Mayo Clinic - Rochester (United States)</p>
10:10 – 10:30 am	<p>LATE BREAKING</p> <p>Late Breaking Biotech Showcase session</p>
10:30 – 11:00 am	<p>Coffee break - poster session and Rising Star Showcase</p>
11:00– 11:25 am	<p>KEYNOTE 4</p> <p>Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials <u>Allan Levey</u>, Professor of Neurology, Emory University's School of Medicine, Emory's Alzheimer's Disease Research Center, Emory University - Atlanta, GA (United States) <i>Introduction: Paul Aisen, ATRI-USC – La Jolla, CA (United States)</i></p>

11 :25 – 12 :25 pm	<p>LATE BREAKING</p> <p>Late Breaking Communications</p>
12 :25– 1 :25 pm	<p>Lunch and poster session</p>
1 :25– 2 :25pm	<p>LATE BREAKING</p> <p>Late Breaking Communications</p>
2 :25 – 3 :10 pm	<p>ORAL COMMUNICATIONS</p> <p>OC35 A proof of concept trial of MIB-626, a sirtuin-NAD+ activator, in mild Alzheimer's disease dementia</p> <p><u>Gad Marshall</u>¹, Karol Pencina², Valentine Shang², Daniel Press³, Scott Mcginnis⁴, Seth Gale⁴, Pamela Friedman⁴, Soyoun Lee⁴, Ricardo Salazar⁵, Brahyan Galindo Mendez⁴, Kirsten Glennon⁴, Danielle Lavey⁴, Alexander Lin¹, Shalender Bhasin²</p> <p>¹Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ²Section on Men's Health, Aging and Metabolism, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ³Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School – Boston, MA (United States), ⁴Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ⁵Division of Geriatric Psychiatry, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States)</p> <p>OC36 Distinct baseline topographies and short-interval spatiotemporal spread of [18F]MK-6240 tau PET in preclinical AD</p> <p><u>Stephanie Doering</u>^{1,2}, Praveen Honhar^{1,2}, Amal Tiss², Charles Chen^{1,2}, Elliott Slade², Emma Thibault², Jackson Thompson², Eva Pintucci², Alex Becker², Michelle Farrell², Reisa Sperling², Julie Price^{1,2}, Keith Johnson², Jessie Fanglu Fu^{1,2}</p> <p>¹Athinoula A. Martinos Center for Biomedical Imaging - Charlestown, MA (United States), ²Massachusetts General Hospital, Harvard Medical School - Boston, MA (United States)</p> <p>OC37 Amyloid and Tau PET Biological Staging Across Ethnoracial Groups in a Multi-Cohort Alzheimer's Disease Study</p> <p><u>Andrzej Sokolowski</u>¹, Karly Cody^{1,2}, Lucah Medina Guerra¹, Isha Sai¹, Emily Johns¹, Alaina Durant³, Derek Archer³, Raul Vintimilla⁴, Sid O'bryant⁴, Timothy Hohman³, Christina Young^{5,6}, Elizabeth Mormino¹</p> <p>¹Department of Neurology and Neurological Sciences, Stanford University – Stanford, CA (United States), ²Department of Neurology, University of California San Francisco - San Francisco, CA (United States), ³Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center – Nashville, TN (United States), ⁴Institute for Translational Research University of North Texas Health Science Center, - Fort Worth, TX (United States), ⁵Department of Radiology, UC Davis – Davis, CA (United States), ⁶Department of Neurology, UC Davis, - Davis, CA (United States)</p>
3:10 – 4:10 pm	<p>LATE BREAKING</p> <p>Late Breaking Oral Communications</p>

POSTER PRESENTATIONS

CLINICAL TRIALS – PHASE IIB & III

P33 Evolution of Late-Stage Alzheimer’s Disease Clinical Trial Design: Toward Biomarker-Driven, Precision Development

Presenter — Laurentiu Gutiu

Abby FULLER (2), Todorova ANTONIYA (3)

(1) Fortrea Germany GmbH, Munich, Germany, (2) Fortrea Inc., Durham, United States, (3) Fortrea Belgium SRL, Brussels, Belgium

P82 Clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients

Presenter — Cheng Fang

Sarah MACCALUM (1), Hui LIU (1), David FENG (2), Maria MACCECCHINI (1)

(1) Annovis Bio, Malvern, United States, (2) TCM, Princeton, United States

P113 Perspectives on the care experience in early Alzheimer’s: Narratives from study partners in the ALTITUDE-AD clinical trial

Presenter — Stephanie Cline

Elizabeth MERIKLE (1), Todd FEASTER (2), Robyn MOXON (2), Eric SIEMERS (2), Dung TRINH (3)

(1) Clinical Outcomes Assessment Consultant, Parksville, Bc, United States, (2) Acumen Pharmaceuticals, Newton, Ma, United States, (3) Healthy Brain Research, Long Beach, Ca, United States

P115 ALTITUDE-AD: Qualitative interviews assessing treatment expectations and motivations for clinical trial participation in early Alzheimer’s disease

Presenter — Stephanie Cline

Elizabeth MERIKLE (1), Todd FEASTER (2), Eric SIEMERS (2), Diana KERWIN (3)

(1) Clinical Outcomes Assessment Consultant, Parksville, Bc, Canada, (2) Acumen Pharmaceuticals, Newton, Ma, United States, (3) Kerwin Medical Center, Dallas, Tx, United States

P148 Evaluation of Sex and APOE4-Related Differences in Baseline Characteristics and Disease Progression Among Placebo-Treated Patients in Anti-Amyloid Alzheimer’s Clinical Trials

Presenter — Kevin Krudys

Athanasios CHAMZAS, Gopichand GOTTIPATI, Ananth Ram NOOKALA, Venkatesh Atul BHATTARAM, Mehul MEHTA, Ramana UPPOOR, Kevin KRUDYS, Sreedharan SABARINATH

Center for Drug Evaluation and Research, FDA, Silver Spring, United States

P161 Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer’s type

Presenter — Ramakrishna Nirogi

Ramakrishna NIROGI, Satish JETTA, Vinod Kumar GOYAL, Vijay BENADE, Anil SHINDE, Santosh Kumar PANDEY, Ramkumar SUBRAMANIAN, Abdul Rasheed MOHAMMED, Dhanunjay DOGIPARTI, Pradeep JAYARAJAN, Venkat JASTI

Suven Life Sciences Ltd, Hyderabad, India

P233 Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease

Presenter — Loes Rutten-Jacobs

Venissa MACHADO (1), Paul EDISON (2), Catherine MUMMERY (3), Alessandro PADOVANI (4), Malu G. TANSEY (5), Silke SIMON (1), Celine ADESSI (1), Nikhat PARKAR (6), Nima SHARIATI (1), Bastian ZINNHARDT (1), Gabriel SCHNETZLER (1), Geoffrey A. KERCHNER (1), Luka KULIC (1), Gennaro PAGANO (1)

(1) F. Hoffmann-La Roche Ltd, Basel, Switzerland, (2) Faculty of Medicine, Imperial College London, London, United Kingdom, (3) Queen Square Institute of Neurology, University College London, London, United Kingdom, (4) Institute of Neurology, University Hospital ASST Spedali Civili of Brescia, Brescia, Italy, (5) Department of Neurology, Indiana University School of Medicine, Stark Neuroscience Research Institute - Indianapolis, Indianapolis, United States, (6) Roche Products Ltd, Welwyn Garden City, United Kingdom

P278 Effect of the P. gingivalis (Pg) gingipain inhibitor atuzaginstat on neuropsychiatric symptoms in Pg-positive mild-moderate AD patients and distress in their caregivers: Analysis of the NPI-12 in the Phase 2/3 GAIN trial

Presenter — Michael Detke

Marwan SABBAGH (2), Joanna BOLGER (1), Tyler DUKE (3), Florian ERMINI (1), Casey LYNCH (1), Stephen DOMINY (1)

(1) Lighthouse Pharma, Novato, United States, (2) Barrow Neurological Institute, Phoenix, United States, (3) Pentara Corp, Millcreek, United States

P294 Standardizing the Unstandardized: Common SAPS H+D Rater Errors in Dementia Trials and a Training Framework to Close the Gap

Presenter — Sayaka Machizawa

Erica APPLEMAN (1), Amanda (Mandy) AEDO (1), Gila BARBATI (1), Alicia CAPECE (1), Joan DEGEORGE (1), Andrei IACOB (2)

(1) Signant Health, Blue Bell, United States, (2) Signant Health, Iasi, Romania

P396 PRImus-AD: Design, Recruitment and Baseline Data of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002

Presenter — Dagmar Jürgens

Dagmar JÜRGENS (1, 2), Gerhard TISCHLER (2), Alexander BRENER (2), Tina BARTSCH (2), Gunther KAUSELMANN (1, 2), Knut ADERMANN (1, 2), Kathrin ZEIGER (2), Katja LINDNER (2), Julie-Anne GABELICH (2), Dieter WILLBOLD (1, 3), Oliver PETERS (1, 4)

(1) Priavoid GmbH, Düsseldorf, Germany, (2) PRInnovation GmbH, Düsseldorf, Germany, (3) Institut für Physikalische Biologie, Heinrich Heine University, Düsseldorf, Germany, (4) Department of Psychiatry and Neuroscience, Charité - Universitätsmedizin Berlin, Berlin, Germany

P443 PRImus-AD: Safety data of the Phase 2b study treating early AD patients with the novel drug candidate PRI-002

Presenter — Gerhard Tischler

Dagmar JÜRGENS (2), Alexander BRENER (1), Tina BARTSCH (1), Gunther KAUSELMANN (1), Knut ADERMANN (2), Kathrin ZEIGER (2), Katja LINDNER (1), Julie-Anne GABELICH (1), Lorenzo BULLI (1), Julia POST-SCHULZ (1), Dieter WILLBOLD (2), Oliver PETERS (2)

(1) PRInnovation GmbH, Düsseldorf, Germany, (2) Priavoid GmbH, Düsseldorf, Germany

P445 Design of a phase 3 clinical trial of the oral p38 α kinase inhibitor neflamapimod in patients with dementia with Lewy bodies (DLB)

Presenter — James Galvin

John-Paul TAYLOR (2), Nathalie ADDA (3), Amanda GARDNER (3), Shannon BRADLEY (3), Kelly BLACKBURN (3), John J ALAM (3)

(1) U. of Miami Miller School of Medicine, Boca Raton, United States, (2) Newcastle University, Newcastle Upon Tyne, United Kingdom, (3) CervoMed Inc, Boston, United States

P481 PRImus-AD: Biomarker Profile Data of the phase 2b study treating early AD patients with the novel drug candidate PRI-002

Presenter — Alexander Brener

Julia POST-SCHULZ (1), Dagmar JÜRGENS (2), Gerhard TISCHLER (1), Tina BARTSCH (1), Gunther KAUSELMANN (2), Knut ADERMANN (2), Kathrin ZEIGER (1), Katja LINDNER (1), Lorenzo BULLI (1), Julie-Anne GABELICH (1), Dieter WILLBOLD (2), Oliver PETERS (2)

(1) PRInnovation GmbH, Düsseldorf, Germany, (2) Priavoid GmbH, Düsseldorf, Germany

P488 ALTITUDE-AD: Baseline characteristics of participants randomized in a phase 2 trial of sabirnetug in early Alzheimer's disease

Presenter — Linda Pao

Todd FEASTER (2), Maddelyn HYLAND (2), Gopalan SETHURAMAN (2), Eric SIEMERS (2)

(1) Jem Research Institute, Atlantis, Fl, United States, (2) Acumen Pharmaceuticals, Newton, Ma, United States

P491 The unique mode of action of the orally applied PRI-002 and its confirmed target engagement in the phase 2b study PRImus-AD

Presenter — Dieter Willbold

Dieter WILLBOLD (1, 2), Dagmar JÜRGENS (1, 3), Gerhard TISCHLER (3), Tina BARTSCH (3), Gunther KAUSELMANN (3, 1), Knur ADERMANN (3, 1), Lorenzo BULLI (3), Katja LINDNER (3), Julia POST-SCHULZ (3), Julie-Anne GABELICH (3), Alexander BRENER (3), Kathrin ZEIGER (3), Oliver PETERS (1, 4)

(1) Priavoid GmbH, Düsseldorf, Germany, (2) Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, (3) PRInnovation GmbH, Düsseldorf, Germany, (4) Department of Psychiatry and Neuroscience, Charité - Universitätsmedizin Berlin, Berlin, Germany

P511 Oral Blarcamesine Clinical Effect In a Phase 2b/3 Early AD Population For SIGMAR1 And Col24a1 Genotypes

Presenter — Marwan Sabbagh

Audrey GABELLE (2), Timo GRIMMER (3), Juan-Carlos TALAVERA (4), Jeffrey EDWARDS (4), Terrie KELLMAYER (4)

(1) Barrow Neurological Institute, Phoenix, United States, (2) University of Montpellier, Montpellier, France, (3) Technical University of Munich, Munich, Germany, (4) Anavex, New York, United States

P530 Effects of Valiltramiprosate on Plasma P-tau217 and Select Pro-Inflammatory and Vascular Injury Biomarkers with the NULISA CNS Panel: Exploratory Analyses from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD

Presenter — Susan Abushakra

John A HEY (1), F. ELAHI (2), David WATSON (3), Aidan POWER (1), Marwan SABBAGH (4), Sharon COHEN (5), Earvin LIANG (6), E. HRISTOVA (6), J. Patrick KESSLAK (6), Susan FLINT (6), Adem ALBAYRAK (6), Martin TOLAR (6)

(1) Alzheon, Inc., Framingham, Ma, United States, (2) Mt. Icahn School of Medicine, Mt. Sinai, New York, Ny, United States, (3) Alzheimer's Research and Treatment Center, Wellington, Fl, United States, (4) Barrow Neurological Institute, Phoenix, Az, United States, (5) Toronto Memory Program, Toronto, On, Canada, (6) Alzheon, Inc, Framingham, Ma, United States

P542 The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial

Presenter — S. Abushakra

E. LIANG (1), M. SABBAGH (2), S. COHEN (3), D. WATSON (4), E. MACSWEENEY (5), Js SAMPALIS (6), J. BARAKOS (7), Jp KESSLAK (1), Ja HEY (1), S. FLINT (1), R. MCLAIN (1), A. ALBAYRAK (1), A. POWER (1), M. TOLAR (1)

(1) Alzheon, Inc, Framingham, Ma, United States, (2) Barrow Neurological Institute, Phoenix, Az, United States, (3) Toronto Memory Clinic, Toronto, On, Canada, (4) Alzheimer's Research and Treatment Center, Wellington, Fl, United States, (5) Re:Cognition Health, London, United Kingdom, (6) McGill University and Université de Montréal, Canada, (7) Clario Inc. & Pacific Medical Center, San Francisco, Ca, United States

P550 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclnx Glasgow.

Presenter — Kanwal Aadil

Kanwal AADIL, Lewis COWAN, Jennifer LYNCH, Fraser INGLIS

Neuroclnx Glasgow, Motherwell, United Kingdom

P634 PUFA Trial Ancillary Biomarker Study: n-3 polyunsaturated fatty acids lower plasma soluble ICAM-1 and NfL in older adults with cerebral small vessel disease

Presenter — Gene Bowman

Yan GAO (1), Lynne SHINTO (2), Charles MURCHISON (3), Hiroko DODGE (1), Pia KIVISAKK (1), Steven ARONOLD (1), Jeffrey KAYE (2), Joseph QUINN (2), Lisa SILBERT (2), Rudolph TANZI (1)

(1) Harvard-MGB, Boston, United States, (2) OHSU, Portland, United States, (3) UAB, Birmingham, United States

P683 The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/A β 42 Ratio in APOE4/4 Homozygotes and their Correlations to Clinical and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD

Presenter — John Hey

Susan ABUSHAKRA (1), Fanny ELAHI (2), Earvin LIANG (1), Patrick KESSLAK (1), Jeremy YU (1), Brian ROTH (1), Susan FLINT (1), Adem ALBAYRAK (1), Elitza HRISTOVA (1), Aidan POWER (1), Martin TOLAR (1)

(1) Alzheon, Framingham, United States, (2) Icahn School of Medicine at Mt. Sinai, New York, United States

P29 Global Exploratory Phase 2 Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of TML-6, a Synthetic Curcumin Analog Targeting the Autolysosomal Pathway in Early Alzheimer's Disease: Study Design and Rationale

Presenter — Hiep Nguyen

Ih Jen SU (1, 2), Chien-Hong LIN (2), Chia-Yu HSU (2), Hui-Chen WANG (2), Feng-Shiun SHIE (4)

(1) Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, Tainan City, Taiwan, (2) Merry Life Biomedical Company, Tainan City, Taiwan, (3) Nguyen Scientific, Encinitas, United States, (4) Center for Neuropsychiatric Research National Health Research Institutes, Zhunan Town, Taiwan

P68 TREMHANCE: A Phase 2 study to evaluate the efficacy and safety of TREM2 agonist SAR448851 in early Alzheimer's disease

Presenter — Jeffrey Cummings

Catherine MUMMERY (2), David WATSON (3), Christopher ROWE (4), Charlotte TEUNISSEN (5), Sebastian PALMQVIST (6), Jeffrey NORTON (7), Sneha NARASIMHAN (8), Stephane HOURCADE (9), Xiaodong LUO (10), Bing ZHU (10), Erik WALLSTROEM (10), Marco COLONNA (11)

(1) University of Nevada Las Vegas, Las Vegas, Nevada, United States, (2) Dementia Research Centre, University College London, London, United Kingdom, (3) Alzheimer's Research and Treatment Center, Wellington, Florida, United States, (4) Austin Health, Heidelberg, Australia, (5) Amsterdam University Medical Center, Amsterdam, The Netherlands, (6) Lund University, Lund, Sweden, (7) Charter Research, The Villages, Florida, United States, (8) Sanofi, Morristown, New Jersey, United States, (9) Sanofi, Vitry-Sur-Seine, France, (10) Sanofi, Cambridge, Massachusetts, United States, (11) Washington University in St. Louis, St. Louis, Missouri, United States

P84 Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): Update on progress in a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate

Presenter — Linda Van Eldik

Wendy ZIAI (2), Lauren SANSING (3), D. Martin WATTERSON (4), Saktimayee ROY (4), Daniel HANLEY (2)

(1) University of Kentucky, Lexington, United States, (2) Johns Hopkins Univ, Baltimore, United States, (3) Yale University, New Haven, United States, (4) Northwestern University, Chicago, United States

P137 NSC001 in Alzheimers's disease: Phase 2a proof of concept of the best in class biased selectove M1 muscarinic agonist

Presenter — Manfred Windisch

Abraham FISCHER (2)

(1) NSC-Therapeutics GmbH, St. Radegund, Austria, (2) ADPD, Holon, Israel

P171 THN391 – A First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: Update of an Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease

Presenter — Nuno Mendonca

Aaron B. KANTOR (1), Tanja A.M. HOFFMAN (1), Sarah KAVANAGH (1), Henk J.M.M. MUTSAERTS (2), Frederik BARKHOF (2), Khalid ABD-ELAZIZ (3), E. Jort G.B. VIJVERBERG (2), Catherine MUMMERY (4), Craig RITCHIE (5)

(1) Therini Bio, Sacramento, Ca, United States, (2) Amsterdam UMC, Amsterdam, The Netherlands, (3) CTC Groningen, Groningen, The Netherlands, (4) University College London Hospitals, London, United Kingdom, (5) Scottish Brain Sciences, Edinburgh, United Kingdom

P178 Early clinical trial findings of AS-S603, a novel small molecule dissociating both amyloid and tau protein aggregates

Presenter — Eosu Kim

Eosu KIM (1, 2), In Young CHANG (1), Seyeon LEE (1), Seong Muk KIM (1), Hye-Ju KIM (1), Seong Jin PARK (1), Youngsoo KIM (1, 2, 3)

(1) Amyloid Solution Inc., Seongnam, Korea, Republic of, (2) Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea, Republic of, (3) College of Pharmacy, Yonsei University, Incheon, Korea, Republic of

P205 Lithium Orotate for Early Stages of Alzheimer Disease and Related Dementias: Design and Methods of a Placebo-Controlled Dose-Ranging Pilot Trial

Presenter — Olivia Okereke

Joann MANSON (2), Pamela RIST (2), Howard SESSO (2), Jennifer GATCHEL (1), Chirag VYAS (1), David MISCHOULON (1), David BENNETT (3), Bruce YANKNER (4)

(1) Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, United States, (2) Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States, (3) Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, United States, (4) Department of Genetics, Harvard Medical School, Boston, United States

P224 First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-16107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects

Presenter — Anil Shinde

Anil SHINDE, Vinod Kumar GOYAL, Veera Raghava Chowdary PALACHARLA, Ramkumar SUBRAMANIAN, Satish JETTA, Pradeep JAYARAJAN, Vijay BENADE, Santosh Kumar PANDEY, Dhanunjay DOGIPARTI, Ilayaraja KALAIKADHIBAN, Abdul Rasheed MOHAMMED, Ramakrishna NIROGI, Venkat JASTI

Suven Life Sciences, Hyderabad, India

P291 Operational Strategies for Executing Complex Multi-Arm Phase 1 Alzheimer's Disease Clinical Trials

Presenter — Liza Moore

Clinilabs, Eatontown, United States

P300 Low-dose levetiracetam to treat cortical hyperexcitability in early Alzheimer's disease: a randomized, double-blind phase 2a crossover trial

Presenter — Stephanie Buss

Stephanie BUSS, Brice PASSERA, Recep OZDEMIR, Emma FERRY, Martina UPTON, Carol ABEDELNOR, Grace DESMOND, Brenna HAGAN, Peter FRIED, Tom TRAVISON, Daniel PRESS, Mouhsin SHAFI

Beth Israel Deaconess Medical Center, Boston, United States

P325 Design of a Phase 2a Trial of LRRK2 Inhibitor HT-4253 in Pre-symptomatic APOE4 Carriers Identified via Population-Scale Genomics and Blood-Based Biomarkers

Presenter — Jeremiah Bearss

Nesrin YASSER (2), Ajisa ALI (3), John KAUWE (4), David BEARSS (1)

(1) HALIA THERAPEUTICS, Utah, United States, (2) HALIA THERAPEUTICS, Dubai, United Arab Emirates, (3) HALIA THERAPEUTICS - Dubai (United Arab Emirates), Dubai, United Arab Emirates, (4) Brigham young university, Hawaii, United States

P339 First-in-Human Study Design of VY1706, a Systemically Administered Blood-Brain Barrier (BBB)-Penetrant Tau Lowering Gene Therapy in Early Alzheimer's Disease

Presenter — Monroe Butler

Monroe BUTLER, Charlotte CHUNG, Joydeep GHOSH, Vik ARORA, Wencheng LIU, Thrusha CHAUHAN, Ivan NESTOROV, Tina OLSSON, Craig MALLINCKRODT, Rajeev SIVASANKARAN, Todd CARTER, Dinah SAH, Alfred SANDROCK, Raj RAJAGOVINDAN, Elena RATTI

Voyager Therapeutics, Lexington, United States

P361 Baseline Characteristics of Participants Enrolled in a Multiple Ascending Dose Study of the C-Terminal Targeting Anti-Tau Antibody VY7523 in Early Alzheimer's Disease

Presenter — Monroe Butler

Monroe BUTLER, Charlotte CHUNG, Joydeep GHOSH, Jennifer MORGAN, Joydip KUNDU, Krishanu MATHUR, Vik ARORA, Wencheng LIU, Craig MALLINCKRODT, Maurice EMERY, Tina OLSSON, Dinah SAH, Alfred SANDROCK, Raj RAJAGOVINDAN, Elena RATTI

Voyager Therapeutics, Lexington, United States

P388 Results from 2 phase 1 studies evaluating the dual FAAH/MAGL inhibitor irafamdestat in healthy adults (including Japanese and elderly)

Presenter — Richard Hargreaves

Thomas LODWEYCKX (1), Jan DE HOON (1), Amina HAGGAG (2), Alice WANG (3), Min CHEN (4), Kevin DINES (4), Joel SCHWARTZ (4), Michael THOMAS (4), Mark THOMAS (4), Anthony KRAKOVICH (4), Yanying WANG (4), Sumit BANSAL (4), Marc GLEICHMANN (3)

(1) Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, Catholic University Leuven, Leuven, Belgium, (2) CenExel, Anaheim, United States, (3) Bristol Myers Squibb (affiliation at time of study), Princeton, United States, (4) Bristol Myers Squibb, Princeton, United States

P399 SAPHARY Phase 1b/2a study to investigate the safety, efficacy, and pharmacokinetics of GAL-101 salt as oral treatment for patients with mild to moderate Alzheimer's disease

Presenter — Katrin Riemann

Bernhard KATGELY (1), Alexander GEBAUER (1), Luciana SUMMO (1), John HARRISON (2), Charlotte TEUNISSEN (3), Willem DE HAAN (4), Andreas BUSJAHN (5), Manfred WINDISCH (6), Hermann RUSS (1)

(1) Galimedix Therapeutics Inc., Kensington, United States, (2) Alzheimercentrum, AUMc, Amsterdam, The Netherlands, (3) Neurochemistry Laboratory, Alzheimer Center Amsterdam UMC, Amsterdam, The Netherlands, (4) Alzheimer Center, Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands, (5) HealthTwist GmbH, Berlin, Germany, (6) NeuroScios GmbH, St. Radegund/graz, Austria

P417 Phase 1b Proof-of-Mechanism Trial of EC5026, a Soluble Epoxide Hydrolase Inhibitor, in Biomarker-Confirmed Early Alzheimer's Disease

Presenter — Myuri Ruthirakuhan

Cindy MCREYNOLDS (2), William SCHMIDT (2), Heather HSU (2), Mario MASELLIS (1), Sandra BLACK (1), Walter SWARDFAGER (1)

(1) Sunnybrook Research Institute, Toronto, On, Canada, (2) EicOsis Human Health Inc., Davis, Ca, United States

P441 Phase 2a clinical trial of the oral p38 α kinase inhibitor neflamapimod in patients with non-fluent variant primary progressive aphasia

Presenter — Ian M. Grant

Hugo BOTHA (2), Lawerance S. HONIG (3), Douglas W. SCHARRE (4), Amanda GARDNER (5), Kelly BLACKBURN (5), Bradley F. BOEVE (2), John J. ALAM (6), David J. IRWIN (7)

(1) Northwestern University, Chicago, United States, (2) Mayo Clinic, Rochester, United States, (3) Columbia University, New York, United States, (4) Ohio State University, Columbus, United States, (5) CervoMed, Inc., Boston, United States, (6) CervoMed Inc., Boston, United States, (7) University of Pennsylvania, Philadelphia, United States

P604 The ABCA1 agonist CS6253 in humans increases plasma apoE and amyloid in plasma and cerebrospinal fluid.

Presenter — Jan Johansson

Bengt WINBLAD (2), Henrik ZETTERBERG (3), Jeffrey CUMMINGS (4), Hussein YASSINE (4)

(1) Artery Therapeutics, Inc., San Ramon, United States, (2) Karolinska Institute, Stockholm, Sweden, (3) Sahlgrenska, Gothenburg, Sweden, (4) UoNevada, Las Vegas, United States

P612 Safety and Modulation of ABCC9 pathways by nicorandil for the Treatment of Hippocampal Sclerosis of aging: The SMaRT-HS Study primary outcome results

Presenter — Gregory Jicha

Gregory JICHA, Erin ABNER, Ahmed BAHRANI, Maria CARRILLO, Elif COSKUN, Danica COY, Alexandra CURTIS, Brian GOLD, Molly HARPER, Emily SMITH, Heather SNYDER, Peter NELSON

University of Kentucky, Lexington, United States

IMAGING (MRI & PET) (31)

P27 Integration of neuroimaging signatures of aging and Alzheimer's disease with plasma biomarkers for the detection and prediction of cognitive impairment

Presenter — Mitzi Gonzales

Ngoc Huynh HO (2), David WANG (2), Sachintha BRANDIGAMPALA (2), Tanweer RASHID (2), Mengjin DONG (2), Sokratis CHARISIS (2), Timothy HOHMAN (3), Sudha SESHADRI (2), Christos DAVATZIKOS (4), Kristine YAFFE (5), Jon TOLEDO (6), Mohamad HABES (2)

(1) Cedars-Sinai, Los Angeles, United States, (2) UT Health San Antonio, San Antonio, United States, (3) Vanderbilt, Nashville, United States, (4) University of Pennsylvania, Philadelphia, United States, (5) University of California San Francisco, San Francisco, United States, (6) Houston Methodist, Houston, United States

P40 The Pronghorn Sign: Hunting for a Radiologic Biomarker in LBD

Presenter — Preston Roche

Preston ROCHE (1), Ashley PARKER (1, 2), Samy ABDULLAH (1), James RINI (3)

(1) UT San Antonio, San Antonio, United States, (2) Biggs Institute, United States, (3) OCHSNER Health, New Orleans, United States

P61 Tau PET signature of amyloid PET visual-positive/quantitative-negative discordance despite low global amyloid burden in ADNI

Presenter — Saki Nakashima

Kenichiro SATO (2), Yoshiki NIIMI (2), Wataru SATAKE (1), Takeshi IWATSUBO (3)

(1) Department of Neurology, Graduate School of Medicine, The University of Tokyo - Tokyo (Japan), Tokyo, Japan, (2) Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, (3) National Center of Neurology and Psychiatry, Tokyo, Japan

P63 Outpatient Medications and Risk of Amyloid-Related Imaging Abnormalities in a Memory Clinic Population Receiving Anti-Amyloid Therapy

Presenter — Sokratis Charisis

Sokratis CHARISIS, John DICKSON, Yingnan HE, Cinthya Aguerro MURILLO, Jeremy N FORD, Michael G ERKKINEN, Liliana A RAMIREZ GOMEZ, Katelyn Mary HORAN, Wedgina NORELUS, Sheena R BARATONO, Elmira HASSANZADEH, Nathan C PRASCHAN, Sudeshna DAS, Kirk R DAFFNER, Teresa GOMEZ-ISLA

Mass General Brigham, Boston, United States

P73 Predictors of ARIA-H in A4 Study: White matter hyperintensity and APOE ε4 selectively influence lobar microhemorrhages

Presenter — Zahra Shirzadi

Nazila LOGHMANI (1), Aaron SCHULTZ (1), Wai-Ying YAU (1), Hyun-Sik YANG (1), Roy YAARI (2), Michael PROPERZI (1), Michael S. RAFIL (3), Clifford R. JACK JR (4), Steven M. GREENBERG (1), Paul AISEN (3), Reisa A. SPERLING (1), Jasmeer P. CHHATWAL (1)

(1) (1) Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, (2) Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States, (3) Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, (4) Mayo Clinic, Radiology, Rochester, United States

P75 Towards clinical CMB detection: a two-stage deep learning approach utilising synthetic data

Presenter — Robin Wolz

Anita KARSA (1), Richard JOULES (1), Jane WAUGH (1), Luigi LORENZINI (2), Frederik BARKHOF (2, 3)

(1) IXICO, London, United Kingdom, (2) Amsterdam UMC, Amsterdam, The Netherlands, (3) University College London, London, United Kingdom

P92 Predictors of longitudinal amyloid clearance due to lecanemab treatment: A preliminary report from a real-world clinical cohort

Presenter — Yuta Katsumi

Neguine REZAILI (1), Kirk DAFFNER (2), John DICKSON (1), Jeremy FORD (1), Seth GALE (2), Teresa GOMEZ-ISLA (1), Gad MARSHALL (2), Liliana RAMIREZ GOMEZ (1), Dennis SELKOE (2), Hyun-Sik YANG (2), Wai-Ying YAU (1), Mark ELDAIEF (1), Scott MCGINNIS (2), Bradford DICKERSON (1)

P118 Do superagers in various cognitive domains show resistance to imaging-based neuropathologies? The Lifeafter90 Study

Presenter — Batool Rizvi

Hilary COLBETH (1), Rifat ALAM (1), Alexander POSIS (1), Katherine COLCORD (2), Charles DECARLI (1), Dan MUNGAS (1), Paola GILSANZ (3), Maria CORRADA (2), Rachel WHITMER (4)

(1) UC Davis, Davis, United States, (2) UC Irvine, Irvine, United States, (3) Kaiser Permanente Northern California Division of Research, Pleasanton, United States, (4) UC Davis, Irvine, United States

P189 Amyloid load in the precuneus is associated with lack of response to anti-amyloid treatment in preclinical Alzheimer's disease.

Presenter — Annalena Venneri

Annalena VENNARI, Matilde GRILLI, Riccardo MANCA

University of Parma, Parma, Italy

P191 Retinal layer thickness predicts cerebral amyloid burden in preclinical Alzheimer's disease

Presenter — Jordan Sergio

Jordan SERGIO (1, 2, 3), Cyrus RAJI (4), Ashley BERNARDO (1, 2), Megan STRADTMAN (5), Savannah A. DOSTER (2, 3), Rachel LACROIX (3, 5), Emma T. LARRACEY (2, 3), Mahshid NAGHASHZADEH (4), Mobina AMANOLLAHI (4), Soheil MOHAMMADI (4), Mona MIRBEYK (4), Mahsa DOLATSHAHI (4), Peter SNYDER (1, 2, 6), Jessica ALBER (1, 2, 3, 6)

(1) Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, United States, (2) Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, United States, (3) Butler Hospital Memory & Aging Program, Providence, United States, (4) Neuroimaging Labs Research Center at Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, United States, (5) Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, United States, (6) George & Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, United States

P219 Advanced Arterial Compliance Impairment Is Associated with Tau Accumulation and Progressive Neurodegeneration

Presenter — Young Noh

Jaelim CHO (2), Yeo Jin KIM (3), Ha-Eun SEO (4), Daegyeom KIM (4), Jihyun BAE (4), Sang-Yoon LEE (5), Kee Hyung PARK (6), Geert Jan BIESELS (7), Jae-Hong LEE (8), Keun-Hwa JUNG (9)

(1) Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea, Republic of, (2) Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of, (3) Department of Neurology, Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of, (4) Neuroscience Research Institute, Gachon University, Incheon, Korea, Republic of, (5) Department of Neuroscience, College of Medicine, Gachon University, Incheon, Korea, Republic of, (6) Department of Neurology, Gachon University Gil Medical Center, Incheon, Korea, Republic of, (7) Department of Neurology, UMC Utrecht, Utrecht, The Netherlands, (8) Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of, (9) Department of Neurology, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of

P230 Burden-dependent bias of cerebellar reference regions in amyloid PET monitoring of disease-modifying therapy: eroded white matter as a calibratable anchor

Presenter — Sang Won Seo

Soo Hyun CHO (2), Seongmi KIM (1), Duk L NA (3), Seongbeom PARK (4), Kichang KWAK (4), Hee Jin KIM (1), Jun Pyo KIM (1), Seunghwan MOON (1)

(1) Samsung medical center, Seoul, Korea, Republic of, (2) Chonnam National University Hospital, Gwangju, Korea, Republic of, (3) Happymind Clinic, Seoul, Korea, Republic of, (4) BeauBrain Healthcare, Seoul, Korea, Republic of

P232 Baseline Radiologic Predictors of ARIA-E and ARIA-H: A Quantitative AI-Supported MRI Analysis of a US Real-World Cohort

Presenter — Mark Pippenger

Nuno PEDROSA DE BARROS (2), Dirk SMEETS (2), Arno LISEUNE (2), Ricardo MAGALHAES (2), Diana SIMA (2), Thibo BILLIET (2), Wim VAN HECKE (2), Aaron RITTER (3), Bela AJTAI (4), Keith SCHLUTERMAN (5), Kinyee FONG (6), Boyang BIAN (6), Nick BELVISO (6), Lydia WOOD (6)

(1) Baptist Health Medical Center, North Little Rock, United States, (2) icometrix, Leuven, Belgium, (3) Hoag Medical Center, Newport Beach, United States, (4) DENT Neurologic Institute, Amherst, United States, (5) Conway Regional Neuroscience Center, Conway, United States, (6) Biogen, Cambridge, United States

P258 Sex, education and race/ethnicity have distinct effects on amyloid and tau-PET status

Presenter — Colin Groot

Colin GROOT, Emma COOMANS, Rik OSSENKOPPELE
Amsterdam UMC, Amsterdam, The Netherlands

P260 Incidence of A β -PET-positivity and tau-PET-positivity in individuals without dementia

Presenter — Emma Coomans

Emma COOMANS (1, 2), Colin GROOT (1, 2), Rik OSSENKOPPELE (1, 2)

(1) Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands, (2) Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

P272 Tau PET Visual Staging of Alzheimer's Disease

Presenter — Emma Ruppert

Marie VERMEIREN (2), Marina SCOP MEDEIROS (1), Thomas KARIKARI (1), David SOLEIMANI-MEIGOONI (3), Juan FORTEA (4), Val LOWE (5), Hwamee OH (6), Belen PASCUAL (7), Brian GORDON (8), Pedro ROSA-NETO (9), Rik OSSENKOPPELE (10), Suzanne BAKER (11), Elsmarieke VAN DE GIESSEN (2), Tharick PASCOAL (1)

(1) University of Pittsburgh, Pittsburgh, United States, (2) Amsterdam UMC, Amsterdam, The Netherlands, (3) University of California San Francisco, San Francisco, United States, (4) Sant Pau Memory Unit, Barcelona, Spain, (5) Mayo Clinic, Rochester, United States, (6) Brown University, Providence, United States, (7) Houston Methodist Research Institute, Houston, United States, (8) Washington University in St. Louis, St. Louis, United States, (9) McGill, Montreal, Canada, (10) Amsterdam Neuroscience, Amsterdam, The Netherlands, (11) Lawrence Berkeley National Laboratory, Berkeley, United States

P286 Distinct Associations Between Hippocampal Subfield Volumes and Episodic Memory in Alzheimer's Disease

Presenter — Giulia Tronchin

Giulia TRONCHIN, Mintao LIU, Tina WANG, Alette Maria WESSELS, Ming LU, Vikas KOTARI, Sergey SHCHERBININ
Eli Lilly and Company, Indianapolis, United States

P304 Therapeutic Amyloid Reduction and Cortical Excitability in Alzheimer's Disease (TRACE-AD) Study Protocol and Early-Stage Findings.

Presenter — Basma Gomaa

Basma GOMAA (1, 2), Stephanie BUSS (1, 2)

(1) Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Boston, United States, (2) Department of Neurology, Harvard Medical School, Boston, United States

P320 Evaluation of atrophy-defined subtypes in early symptomatic Alzheimer's disease

Presenter — Vikas Kotari

Mintao LIU, Vikas KOTARI, Jiaying GUO, Adam S. FLEISHER, Rik OSSENKOPPELE, Sergey SHCHERBININ
Eli Lilly and Company, , United States

P323 MRI-based enrichment for pathology-targeted progressive supranuclear palsy trials in non-fluent variant primary progressive aphasia

Presenter — Jesús García-Castro

María Luisa MANDELLI (2), Alexandre BEJANIN (1), Oriol DOLS-ICARDO (1), Juan FORTEA (1), Daniel ALCOLEA (1), Alberto LLEÓ (1), Kejal KANTARCI (3), Hilary W. HEUER (2), Howard ROSEN (2), Brad BOEVE (3), Adam BOXER (2), Zachary MILLER (2), María Luisa GORNO-TEMPINI (2), Ignacio ILLÁN-GALA (1)

(1) Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (2) Memory and Aging Center, UCSF, San Francisco, United States, (3) Mayo Clinic, Rochester, United States

P351 Tau PET spatial patterns for trial-relevant measurement of tau progression in preclinical AD: AHEAD-3/45 and HABS

Presenter — Jessie Fanglu Fu

Stephanie DOERING (1), Praveen HONHAR (1), Amal TISS (1), Emma THIBAUT (1), Eva PINTUCCI (1), Elliott SLADE (1), Alex BECKER (1), Michelle FARRELL (1), Michael PROPERZI (1), Aaron SCHULTZ (1), Reisa SPERLING (1), Julie PRICE (1), Keith JOHNSON (1), Actc AHEAD 3-45 STUDY TEAM (2)

(1) Massachusetts General Hospital, Boston, United States, (2) Alzheimer Clinical Trials Consortium, , United States

P461 AIND: A Validated AI-Derived Neurodegeneration Marker for Alzheimer's Disease Clinical Trials

Presenter — David Vaillancourt

Jesse DESIMONE (2), Robin CHEN (1), Shannon CHIU (3), Wei-En WANG (1), Freydel ESPINOZA-URBINA (1), Angelos BARMPOUTIS (1)

(1) University of Florida, Gainesville, United States, (2) Neuropacs, Gainesville, United States, (3) Mayo Clinic, Phoenix, United States

P467 Longitudinal evolution of enlarged perivascular spaces across the AD continuum

Presenter — Luc Bracoud

Alessandro DELMONTE (1), Thomas CAJGFINGER (1), Madhura INGALHALIKAR (2), Chris CONKLIN (2), Joel SCHAEERER (3), Meredith BURKE (2), David SCOTT (2)

(1) Clario, part of Thermo Fisher Scientific, Lyon, France, (2) Clario, part of Thermo Fisher Scientific, Philadelphia, United States, (3) Clario, part of Thermo Fisher Scientific, Geneva, Switzerland

P472 Comparison of test-retest variability and longitudinal stability of total intracranial volume measurement between atlas-based and segmentation-based MRI methods

Presenter — Luc Bracoud

Thomas CAJGFINGER (1), Alessandro DELMONTE (1), Madhura INGALHALIKAR (2), Chris CONKLIN (2), Joel SCHAEERER (3), Meredith BURKE (4), David SCOTT (4)

(1) Clario, part of Thermo Fisher Scientific, Lyon, France, (2) Clario, part of Thermo Fisher Scientific, Philadelphia, United States minor outlying islands, (3) Clario, part of Thermo Fisher Scientific, Geneva, Switzerland, (4) Clario, part of Thermo Fisher Scientific, Philadelphia, United States

P554 Contribution of the automated MRI segmentation of the brain trophicity in the diagnosis of Lewy Body Disease in a clinical center

Presenter — Claire Paquet

Christine DELMAIRE (1), Julien SAVATOVSKY (2), Claire HOURREGUE (3), Esteban MUNOZ (3), Emmanuel MORAIN (3), Fabien HAUW (3), Agathe VRILLON (3)

(1) Fondation Rothschild, Radiology, Paris, France, (2) Fondation Rothschild, Radiology - Paris (France), Paris, France, (3) Hôpital Fernand Widal, Assistance Publique Hôpitaux de Paris, Centre de Neurologie Cognitive - Paris (France), Paris, France

P593 Radiology Inferred CAA as a Potential Biomarker: Links to Pathology Timing, Cognition, and Proteomics

Presenter — Julie Oomens

Ramiro Eduardo REA REYES (1), Leonardo RIVERA-RIVERA (1), Mai ABDELMOATY (2), Rachael WILSON (2), Sterling JOHNSON (1)

(1) Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, (2) Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P601 Predicting Amyloid PET Positivity from a Brief Digital Cognitive Assessment in Memory Clinic Patients

Presenter — Ali Jannati

David LIBON (1), Mitchel KLING (1), Kallie SWEETMAN (1), Jacqueline NGUYEN (1), Ileana DE ANDA-DURAN (3), Rod SWENSON (4), Sean TOBYNE (2), Alvaro PASCUAL-LEONE (2, 5)

(1) Rowan University, Glassboro, United States, (2) Linus Health, Boston, United States, (3) Tulane University, New Orleans, United States, (4) University of North Dakota, Grand Forks, United States, (5) 2Hebrew SeniorLife - Harvard Medical School, Boston, United States

P662 Anti-Amyloid Therapy Accelerates Amyloid-Dependent Perivascular Diffusivity Decline and Amyloid-Independent White Matter Hyperintensity Progression

Presenter — Hanna Cho

Han Soo YOO (1), Daeun SHIN (1), Hye Sun LEE (2), Seul Ki JEONG (1), Bio JOO (3), Mina PARK (3), Sung Jun AHN (3), Jae Hoon LEE (4), Young Hoon RYU (4), Chul Hyoung LYOO (1)

(1) Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, (2) Department of Research Affairs, Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea, Republic of, (3) Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, (4) Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

P678 Portable, Low-field MRI Combined with Machine Learning Segmentation for Cognitively Impaired Individuals

Presenter — Ava Farnan

Ava FARNAN (1, 2), Annabel J. SORBY-ADAMS (1, 2), John R. DICKSON (1), Liliana RAMIREZ GOMEZ (1), Arman FESHARAKI-ZADEH (3), Christopher VAN DYCK (4), Matthew S. ROSEN (5), Kevin N. SHETH (4), J. Eugenio IGLESIAS (6), Adam DE HAVENON (4), Teresa GOMEZ-ISLA (1), Alberto SERRANO POZO (1), W. Taylor KIMBERLY (7, 2)

(1) Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United States, (2) Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States, (3) Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA, New Haven, United States, (4) Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, New Haven, United States, (5) Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA - United States, Boston, United States, (6) Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United States, (7) Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, Boston, United States

P681 A practical correction for non-specific [18F]MK-6240 uptake to improve tau PET quantification for early detection

Presenter — Praveen Honhar

Jessie FANGLU FU (1), Amal TISS (2), Michael PROPERZI (3), Aaron SCHULTZ (1), Julie PRICE (1), Keith JOHNSON (1)

(1) Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, United States, (2) Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, United States, (3) Massachusetts General Hospital, Boston, United States

P686 Point-of-Care Low-Field MRI for Monitoring ARIA-E and Pseudoatrophy During Anti-Amyloid Therapy

Presenter — Annabel Sorby-Adams

Ava FARNAN (1), Shenghua ZHU (1), John R. DICKSON (1), Liliana RAMIREZ-GOMEZ (2), Alberto SERRANO-POZO (1), Arman FESHARAKI-ZADEH (3), Matthew S. ROSEN (4), Jeremy FORD (5), Kevin N. SHETH (3), Adam DE HAVENON (3), J. Eugenio IGLESIAS (4), Teresa GOMEZ-ISLA (1), W. Taylor KIMBERLY (1)

(1) Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, United States, (2) Department of Neurology, Mass General Brigham and Harvard Medical School - Boston, Boston, United States, (3) Yale Center for Brain & Mind Health, Yale New Haven Hospital and Yale Medical School, New Haven, United States, (4) Athinoula A. Martinos Center for Biomedical Imaging, Mass General Brigham and Harvard Medical School, Boston, United States, (5) Department of Radiology, Mass General Brigham and Harvard Medical School, Boston, United States

ARTIFICIAL INTELLIGENCE ⁽⁶⁾

P182 AI-Enabled Analysis of Anti-A β Clinical Trial Outcomes Supports Investigation of the Neurogenesis-Based Therapeutic Candidate NA-831 for Alzheimer's Disease

Presenter — Lloyd Tran

Lloyd TRAN, Michael WILLIS, Zung TRAN

Biomed AI, Inc., San Jose

P185 Characteristics, trajectories, and Alzheimer's disease biomarkers in subjective cognitive decline: a proposal for a management framework in clinical and research settings

Presenter — Salvatore Mazzeo

Salvatore MAZZEO (1, 2), Michael LASSI (3), Sonia PADIGLIONI (4, 5), Alberto Arturo VERGANI (3, 6), Valentina MOSCHINI (4), Giulia GIACOMUCCI (4), Carmen MORINELLI (4), Silvia BAGNOLI (7), Assunta INGANNATO (7), Maria SALSONE (1, 2), Massimo FILIPPI (8), Benedetta NACMIAS (7, 9), Antonello GRIPPO (10, 9), Alberto MAZZONI (3), Valentina BESSI (10, 7)

(1) Neurology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy, (2) Vita-Salute San Raffaele University, Milan, Italy, (3) The BioRobotics Institute and Department of Excellence in Robotics and AI, Scuola Superiore Sant'Anna, Pisa, Italy, (4) SOD Neurologia, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, Florence, Italy, (5) Regional Referral Centre for Relational Criticalities - Tuscany Region, Florence, Italy, (6) Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy, (7) Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, (8) Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, "Vita-Salute" San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy, (9) IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy, (10) SODC Neurofisiopatologia, Azienda Ospedaliero-universitaria Careggi, Florence, Italy

P209 Artificial Intelligence-Guided Drug Repurposing for Alzheimer's Disease Based on the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases

Presenter — Lloyd Tran

Lloyd TRAN, Michael WILLIS, Zung TRAN

Biomed AI, Inc., San Jose, United States

P477 AI-based prognostic stratification accurately predicts future clinical decline and increases observed decline in symptomatic and preclinical AD placebo arms

Presenter — Luca Villa

Luca VILLA, Zi Hui SU, Ayoub GUEDDOU, Mathilde BORROT, Nicolas GUIZARD, Elizabeth GORDON

Qynapse, 2-10 rue d'Oradour-sur-Glane, 75015 Paris, France, Paris, France

P616 AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer's Disease Trial

Presenter — Phil Kang

Phil KANG, Lisa VADEN, Ja Yeon SHIN, Fred KIM, Jai Jun CHOUNG

AriBio Co., Ltd., San Diego, United States

P713 FINGERS-7B: A Multi-Omic Foundation Model for Precision Biomarker Discovery

Presenter — Arvid Gollwitzer

Arvid GOLLWITZER (1, 2), Adrian NORIEGA DE LA COLINA (1, 2, 3), Li-Huei TSAI (1, 4), Miia KIVIPELTO (5, 6), Giovanni TRAVERSO (1, 2, 7)

(1) Broad Institute of MIT and Harvard, Cambridge, United States, (2) Massachusetts Institute of Technology, Cambridge, United States, (3) Brigham and Women's Hospital, Boston, United States, (4) The Picower Institute for Learning and Memory, Cambridge, United States, (5) FINGERS Brain Health Institute, Stockholm, Sweden, (6) Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, (7) Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States

EPIDEMIOLOGY ⁽¹⁶⁾

P18 Cognitive Reserve Indicators Modify the Association Between Cardiovascular Health and Cognitive Function in a Community-Based Population

Presenter — Wang Dandan

Wang ANXIN (1), Wu SHOULING (2), Zhao XINGQUAN (1)

(1) Beijing Tiantan Hospital, Beijing, China, (2) Kailuan Hospital, Tangshan, China

P39 Updated Results from a Post-Marketing Observational Study of Lecanemab in Japan

Presenter — Atsushi Iwata

Sakata YUKINORI (2), Koizumi KINUYO (2), Kanekiyo MICHIO (3), Dhadda SHOBHA (3), Endo AKIRA (2), Kuang WEIJIE (2), Sakamoto YUSUKE (2), Sumitomo KENTA (2), Ishii MIKA (2), Iwatsubo TAKESHI (4)

(1) Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (2) Eisai Co., Ltd., Tokyo, Japan, (3) Eisai Inc., New Jersey, United States, (4) National Center of Neurology and Psychiatry, The University of Tokyo Hospital, Tokyo, Japan

P60 The population-level impact of herpes zoster vaccination on dementia-related and all-cause mortality: Evidence from country-wide death certificate data for England

Presenter — Pascal Geldsetzer

Felix MICHALIK (1), Disser MICHELLE (1), Seunghun CHUNG (1), Min XIE (1), Markus EYTING (1), Mark JOY (2), Simon DE LUSIGNAN (2), Aziz SHEIKH (2)

(1) Stanford University, Stanford, United States, (2) Oxford University, Oxford, United Kingdom

P79 Distinct Temporal Profiles of ARIA Subtypes During Donanemab Treatment: Real-World Experience from a Japanese Single-Center Cohort

Presenter — Taro Bannai

Taro BANNAI (1), Ryoko IHARA (1, 2), Masanori KURIHARA (1, 2), Ryosuke SHIMASAKI (1, 2, 3), Keiko HATANO (1), Fumio SUZUKI (4), Aya MIDORI TOKUMARU (4), Toshiaki AKASHI (4), Kenji ISHII (2, 5), Atsushi IWATA (1, 2)

(1) Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (2) Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (3) Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, (4) Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (5) Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P103 Clinical Practice Outcomes with Lecanemab for Alzheimer's Disease

Presenter — Andy Liu

Duke University, United States

P108 Systemic inflammation and longitudinal trajectory of cognition and blood-based biomarkers of Alzheimer's Disease in a multiethnic community-based cohort

Presenter — Yian Gu

Yian GU, Lawrence HONIG, Kang MIN SUK, Sanchez DANURYS, Reyes-Dumeyer DOLLY, Manly JENNIFER, Brickman ADAM, Mayeux RICHARD

Columbia University, New York, United States

P128 Association of Ginseng Intake and Serum Zinc with Alzheimer's Disease-Related Cognition

Presenter — Shin Gyeom Kim

Young Min CHOE (1), Jee Wook KIM (1)

(1) Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, (2) Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of

P180 Inflammatory Arthritis and Dementia

Presenter — Jun Hong Lee

National Health Insurance Service Ilsan Hospital, Goyang-Si, Korea, Republic of

P204 Peri-infusion Blood Pressure Reactivity as a Non-Invasive Marker of Cerebrovascular Amyloid Burden during Lecanemab Treatment in Early Alzheimer's Disease

Presenter — So Yeon Jeon

Byung-Hyug CHOI (1), Jung Hwan KIM (2), Yu Kyeong KIM (1), Jun-Young LEE (1)

(1) SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, (2) Seoul National University College of Medicine, Seoul, Korea, Republic of

P215 Time Savings and Patient Preference for Subcutaneous Injection Versus Intravenous Infusion of Lecanemab

Presenter — Cara Leahy

Victor FARADJI (2), Lara MARCEL (2), Feride FRECH (3), Hideki TOYOSAKI (3), Dean SMITH (4)

(1) Memorial Healthcare Institute for Neuroscience, Owosso, United States, (2) First Choice Neurology and Visionary Investigators Network (VIN), Miami, United States, (3) Eisai Inc., Nutley, United States, (4) School of Public Health, University of Michigan, Ann Arbor, United States

P268 Characterization of Serious ARIA Events from Approved Amyloid Antibodies: Real World Analysis of Spontaneous Reports FDA Adverse Event Monitoring System (AEMS)

Presenter — Soeren Mattke

Tabasa OZAWA (1), Susan ABU-SHAKRA (2), John HEY (2)

(1) University of Southern California, , United States, (2) Alzheon, , United States

P271 The effect of herpes zoster vaccination on full-time care use in people with and without cognitive complaints: a causal inference study using Swedish record-linkage data

Presenter — Pieter Van Der Veere

Emil AHO (1), Johansson NAIMI (1), Lövheim HUGO (2), Jönsson LINUS (1)

(1) Karolinska Institutet, Stockholm, Sweden, (2) Umeå University, Umeå, Sweden

P452 Pathology-Informed Polygenic Scores Identify Distinct Genetic Contributors to Alzheimer's and Non-Alzheimer's Dementia Across Ancestries

Presenter — Yuexuan Xu

Tamil GUNASEKARAN (1), Yian GU (1), Lawrence HONIG (1), Jennifer MANLY (1), Adam BRICKMAN (1), Corinne ENGELMAN (2), Sterling JOHNSON (2), Sid O'BRYANT (3), Caghan KIZIL (1), Badri VARDARAJAN (1), Richard MAYEUX (1)

(1) Columbia University, New York, United States, (2) University of Wisconsin-Madison, Madison, United States, (3) University of North Texas Health Science Center, Fort Worth, United States

P518 Population-Adjusted Alzheimer's Clinical Trial Capacity in the United States: Reassessing the Perception of Site Saturation in High-Burden States

Presenter — Sean Stanton

Sean STANTON, Sameer SADDIQI, Taylor RICE, Brandon LENOX, Craig CURTIS

K2 Medical Research, Orlando, United States

P586 A Bayesian Data-Integration Framework for Estimating Diagnosed and Undiagnosed Dementia Burden at the County and State Level

Presenter — Carolina Franco

Carolina FRANCO, Gianattasio KAN, Rein DAVID

NORC at the University of Chicago, Dunkirk, United States

P688 From Diuresis to Dementia Prevention: How Carbonic Anhydrase Inhibitors May Modulate Dementia Risk in Glaucoma Patients

Presenter — Rachel Dolan

Reagan MCGINLEY (2), Estevao RIBEIRO (3), Andrew MELSON (4), Claire DELPIROU NOUH (5)

(1) University of Oklahoma College of Medicine, University of Oklahoma Health Campus, Oklahoma City, United States, (2) Baylor College of Medicine, Houston, United States, (3) Department of Neurology, University of Oklahoma Health Campus - Oklahoma City (United States), Oklahoma City, United States, (4) Dean McGee Department of Ophthalmology, University of Oklahoma Health Campus, Oklahoma City, United States, (5) Department of Neurology, University of Oklahoma Health Campus, Oklahoma City, United States

NEW HYPOTHESES – NEW THERAPEUTIC APPROACHES FOR AD ⁽²⁰⁾

P9 Concept for a Trial of Immunomodulatory Therapy with BCG to Prevent Progression of Preclinical Alzheimer's Disease

Presenter — Pierre Tariot

Inga ANTONSDOTTIR (2), Steven ARNOLD (3), Nicholas ASHTON (4), William BISHAI (2), Corey CASPER (5), Marisa DENKINGER (6), Denise FAUSTMAN (3), Pascal GELDSETZER (7), Tiffany HENSLEY-MCBAIN (8), Joe JIANG (9), Jennifer KNOX (1), Donald LAMM (10), Jeremy PRUZIN (1)

(1) Banner Alzheimer's Institute, Phoenix, United States, (2) Johns Hopkins Medicine, Baltimore, United States, (3) Mass General Brigham, Boston, United States, (4) Banner Sun Health Research Institute, Phoenix, United States, (5) Banner Health, Phoenix, United States, (6) Banner Sun Health Research Institute's Institute, Phoenix, United States, (7) Stanford Medicine, Palo Alto, United States, (8) McLaughlin Research Institute, Great Falls, United States, (9) DFnet, Seattle, United States, (10) University of Arizona, Phoenix, United States

P14 Dissociated MAS1 Receptor and Effector Expression Identifies a Failed Compensatory State in Human Vascular Cognitive Impairment: Implications for Therapeutic Strategy

Presenter — Meredith Hay

University of Arizona, Tucson, United States

P15 Pipeline Diversification and Emerging Therapeutic Hypotheses in Alzheimer's Disease

Presenter — Laurentiu Gutiu

Abby FULLER (2), Antoniya TODOROVA (3)

(1) Fortrea Germany GmbH, Munich, Germany, (2) Fortrea Inc., Durham, United States, (3) Fortrea Belgium SRL, Brussels, Belgium

P42 Multidimensional Evaluation of Deep Cervical Lymphatic-Venous Anastomosis and Lymphatic sternectomy in Alzheimer's Disease: A 12-Month Single-arm Prospective Study

Presenter — Yan Chen

Chenpeng ZHANG (2), Jing WANG (3), Yang YANG (1), Qianqian GUO (1), Ziyi LIU (1), Chuantao ZUO (3), Ren ZHENGHU (4), Xia LI (1)

(1) Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, (2) Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, (3) Department of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China, (4) Department of Oral and Maxillofacial & Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China

P49 Alzheimer's Disease Is a Multi-Protein Disorder: Mechanistic and Clinical Evidence for a New Therapeutic Framework

Presenter — Maria Maccacchini

Annovis Bio, Malvern, United States

P65 Modulation of Fibronectin-1 Restores Blood-Brain Barrier Integrity and Gliovascular Signaling in APOE ϵ 4-Associated Alzheimer's Disease

Presenter — Caghan Kizil

Prabesh BHATTARAI (1), Elanur YILMAZ (1), Tal NURIEL (2), Badri VARDARAJAN (1), Richard MAYEUX (1)

(1) 1Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA, New York City, United States, (2) 2Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA, New York City, United States

P95 Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease

Presenter — Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

Biomed Industries, Inc., San Jose, United States

P99 Therapeutic plasma exchange with albumin replacement via peripheral access in Alzheimer's disease: real-world evidence on cognitive outcomes in a single-center cohort from ACE Alzheimer Center Barcelona

Presenter — Mercè Boada

Mercè BOADA (1, 2), Yahveth CANTERO-FORTIZ (1, 3), Federico CASALES (1), Sergi VALERO (1), Genis CARRASCO (1), Oscar BASCUÑANA (1), Berta CALM (1), Adrián HINOJOSA (1), Emilio ALARCÓN-MARTÍN (1), Amanda CANO (1), Victoria FERNÁNDEZ (1), Xavier MORATÓ (1), Antonio PAÉZ (4), Natalia LOPÉZ DEL HOYO (1), Xavier MONTALBAN (1, 5)

(1) Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, (2) Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, (3) Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, (4) Neuro-Innovation Hub, Grífols, Barcelona, Spain., Barcelona, Spain, (5) Universitat de Vic-central de Catalunya (UVic-UCC), Barcelona, Spain

P100 Outpatient therapeutic plasma exchange with albumin replacement via peripheral access in Alzheimer's disease: real-world safety and feasibility in a single-center cohort from ACE Alzheimer Center Barcelona

Presenter — Mercè Boada

Mercè BOADA (1, 2), Yahveth CANTERO-FORTIZ (1, 2), Federico CASALES (1), Sergi VALERO (1), Genis CARRASCO (1), Oscar BASCUÑANA (1), Berta CALM (1), Adrián HINOJOSA (1), Emilio ALARCÓN-MARTÍN (1), Amanda CANO (1), Victoria FERNÁNDEZ (1), Xavier MORATÓ (1), Antonio PAÉZ (3), Basilio HERNÁNDEZ (3), Xavier MONTALBAN (1, 4)

(1) Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, (2) Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, (3) Neuro-Innovation Hub, Grífols, Barcelona, Spain, (4) Universitat de Vic-central de Catalunya (UVic-UCC)4, Barcelona, Spain

P105 Clinical Translational Studies to Understand the Role and Pathogenic Mechanisms of Basal Forebrain Cholinergic Neuronal (BFCN) Degeneration in the Major Dementias

Presenter — John Alam

John ALAM (1), Paul MARUFF (2, 3)

(1) CervoMed, Inc, Boston, United States, (2) Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, (3) Cogstate, Ltd, Melbourne, Australia

P141 Treatment of age-related upstream bioenergetic and redox impairment promotes clearance of A β and tau aggregates, lowers oxidative nitration and promotes synapse formation in isolated neurons from AD mouse models

Presenter — Gregory Brewer

Svara SHAH (1), Ricardo SANTANA (2)

(1) UC Irvine, Irvine, United States, (2) UNAM, Mexico City, Mexico

P159 Is cerebral A β 42-amyloidosis (CAB42-A) a more appropriate labelling for asymptomatic patients than Alzheimer's disease?

Presenter — Michaela Defrancesco

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P168 Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer's Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke

Presenter — Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN

Biomed Industries, Inc., San Jose, United States

P266 Topline results of a Phase IV trial of EGb761 in patients with Mild Cognitive Impairment: ACE-2020-EGb761

Presenter — Xavier Morato Arus

Marta MARQUÍ (1), Juan Pablo TARTARI (1), Asunción LAFUENTE (1), Marai Eugenia SÁEZ (2), Sara JOFRESA (1), Laia MONTOLIU-GAYÀ (3), Marta IBARRIA (4), Susana DIEGO (4), Mar BUENDIA (4), Nuria AGUILERA (4), Natalia TANTINYA (4), Laia CAÑADA (4), Pilar SANZ (4), Mercè BOADA (4)

(1) Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain, (2) 3CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain, (3) University of gothenburg, Mölndal, Sweden, (4) Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Sweden

P447 Computerized Olfactory Adaptive Training (COAT) Improves Hyperconnectivity in the Medial Temporal Lobe Networks in Patients with Mild Cognitive Impairments: a Randomized Clinical Trial

Presenter — Evaristus A. Nwulia

Opeyemi Mercy AWOFOESO (1), Maria HIPOLITO (2), Ashley VANMETER (3), Narayan RAI (2), Tamal SADHUKHAN (2), Claudia Ivonne Mejia MONDRAGÓN (2), Haroon S POPAL (1), Van Hecke KINNEY (3), Rebecca AITKEN (3), Adedoyin KALEJAIYE (2), Vamsi REDDY (1), Jamal MONGER (1), Charles NWAOKOBIA (1), Thomas OBISESAN (2)

(1) Evon Medics, Ellicott City, United States, (2) Howard University, Washington Dc, United States, (3) Georgetown University Medical Center Evon Medics, Washington Dc, United States

P501 Phase 1 Clinical Development Strategy for PNA5 in VCID: Translational Biomarkers, Neurovascular Mechanisms, and SAD/MAD Design

Presenter — Meredith Hay

Meredith HAY, Tamara CROCKETT

ProNeurogen, Inc, Tucson, United States

P524 Feasibility of a multidomain intervention combining Reduced carbohydrate intake, Omega-3 fatty acids, MCT supplementation, and EXercise in older adults at risk of Alzheimer's disease: the ROMEX-AD trial.

Presenter — Melanie Fortier

Christian BOCTI (1), Mark ESPELAND (2), Matthew PHILLIPS (3), Stephen CUNNANE (1)

(1) Research Center on Aging and Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada, (2) Wake Forest University School of Medicine, Winston-Salem, United States, (3) Research Center on Aging and Department of Medicine, Université de Sherbrooke, Hamilton, New Zealand

P538 Real-World Effects of Therapeutic Plasma Exchange With Albumin Replacement on Inflammatory Biomarkers Across the Alzheimer's Disease Continuum

Presenter — Xavier Morato

Caatherine DEMOS (2), Yahveth CANTERO (1), Federico CASALES (1), Emilio ALARCÓN-MARTIN (1), Oscar BASCUÑANA (1), Victoria FERNANDEZ (1), Amanda CANO (1), Jordi KLAMBURG (1), Antonio PAEZ (3), Basilio HERNANDEZ (3), Natalia LOPEZ DEL HOYO (3), Anu MATHEW (3), Xavier MONTALBAN (1), Mercè BOADA (1)

(1) Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, (2) Meso Scale Diagnostics, LLC., Rockville, United States, (3) Neuro-Innovation Hub, Grifols, Barcelona, Spain

P552 APP-CTF accumulation: a key factor of APP dyshomeostasis in Alzheimer's disease

Presenter — Alberto Lleo

Alberto LLEO, Sánchez-Aced ERIKA, Moya BORJA, Sonia SIRIRI

Hospital Sant Pau, Barcelona, Spain

P694 A common Alzheimer's disease-linked HLA-DRB1 genetic variant potentiates tau-associated microglial reactivity

Presenter — João Pedro Ferrari-Souza

Celia BIANCO (1), Marco Antônio DE BASTIANI (2), Huan LI (1), Methasit JAISA-AAD (1), Giovanna CARELLO-COLLAR (2), Swarnali DASGUPTA (1), Akhila GUNDAVELLI (1), Srinija ALLA (1), Jordan MARKS (1), Bradley HYMAN (1), Eduardo ZIMMER (2), Sudeshna DAS (1), Alberto SERRANO-POZO (1)

(1) Massachusetts General Hospital, Boston, United States, (2) Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

NON-PHARMACOLOGIC INTERVENTIONS (18)

P51 Implementing Brain Health Services for the Secondary Prevention of Cognitive Impairment and Dementia in Real-World Settings: Insights from the International dBHS Network

Presenter — Federica Ribaldi

Oriol GRAU-RIVERA (2), Ayda ROSTAMZADEH (3), Francesca MANGIALASCHE (4), Stefano CAPPA (5), Giovanni B FRISONI (1)

(1) University of Geneva, Geneva, Switzerland, (2) BarcelonaBeta Brain Research Center, Barcelona, Spain, (3) University of Cologne, Cologne, Germany, (4) Karolinska Institutet, Stockholm, Sweden, (5) IRCCS Istituto Auxologico Italiano, Milan, Italy

P101 Impact of a Multidomain Lifestyle Intervention on Gut Microbiota: An Exploratory Sub-study of the SUPERBRAIN Trial

Presenter — Seong Hye Choi

Jee Hyang JEONG (2), Yangki MINN (3), Woorim KANG (4), So Young MOON (5), Yoo Kyoung PARK (6)

(1) Inha University College of Medicine, Incheon, Korea, Republic of, (2) Ewha Womans University School of Medicine, Seoul, Korea, Republic of, (3) Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea, Republic of, (4) Kangwon National University, Chuncheon, Korea, Republic of, (5) Ajou University School of Medicine, Suwon, Korea, Republic of, (6) Graduate School of East-West Medical Nutrition, Kyung Hee University, Yongin, Korea, Republic of

P134 Nutritional Status and Cognitive Function: Role of Apolipoprotein E ε4 in the Elderly

Presenter — Shin Gyeom Kim

Young Min CHOI (1), Jee Wook KIM (1)

(1) Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, (2) Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of

P151 Can Menopausal Status Moderate the Effects of Aerobic Exercise on Executive Functions? Evidence from a Randomized Controlled Trial

Presenter — Sharon Sanz Simon

Maya GAL (2), Seonjoo LEE (3), Marcella D. WALKER (3), Michal S. BEERI (1), Gloria BACHMAN (1), Vincenzo LAURIOLA (3), Richard SLOAN (3), Yunglin GAZES (4)

(1) Rutgers University, New Jersey, United States, (2) Albert Einstein College of Medicine, New York, United States, (3) Columbia University, New York, United States, (4) The Nathan Kline Institute for Psychiatric Research, New York, United States

P184 Early Detection of cognitive Decline and Dementia prevention in women: the 3D study protocol

Presenter — Salvatore Mazzeo

Salvatore MAZZEO (1, 2), Federico Emanuele POZZI (1), Elisa BORTOLIN (1, 2), Giulia BRUSCHI (1, 2), Arianna FRIJO (1), Alessandro BOMBACI (1, 2), Gianni CUTILLO (1, 2), Eleonora FERRANTE (1), Laura RENNA (3), Rosanna CARDANI (3), Massimo FILIPPI (4), Maria SALSONE (1, 2)

(1) Neurology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy, (2) Vita-Salute San Raffaele University, Milan, Italy, (3) BioCor Biobank, IRCCS Policlinico San Donato, San Donato Milanese, Italy, (4) Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy

P261 PodCaring: Investigating the Feasibility and Efficacy of the Dementia Untangled Podcast for Caregivers and Patients with Early-Stage Cognitive Impairment

Presenter — Jasmine Zhang

Heather L. MULDER (2), Nellie M. HIGH (2), Robert J. BAUER (2), Jennifer C. KNOX (2), Yinghua CHEN (2), Lori NISSON (2), Jessica B. LANGBAUM (2), Amber D. AYERS (3), Matthew J. HUENTELMAN (4), David COON (5), Jeremy J. PRUZIN (2)

(1) University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, United States, (2) Banner Alzheimer's Institute, Phoenix, Arizona, United States, (3) Banner Alzheimer's Institute, Tucson, Arizona, United States, (4) Translational Genomics Research Institute, Phoenix, Arizona, United States, (5) Arizona State University Edson College of Nursing and Health Innovation, Phoenix, Arizona, United States

P273 Factors contributing to retention in a mobile telehealth intervention trial for dementia caregivers.

Presenter — Miriam Jocelyn Rodriguez

Jordan HILL (1), Mariana STAVIG (1), Roger ZOH (1), Anna MACAGNO (1), Agnis DUAH (1), Malaz BOUSTANI (2), Richard HOLDEN (1)

(1) Indiana University, Bloomington, United States, (2) Indiana University, Indianapolis, United States

P276 A Care Coach protocol for caregivers of persons with dementia (PWD) to help manage behavioral and psychological symptoms of dementia (BPSD).

Presenter — Miriam Jocelyn Rodriguez

Miriam Jocelyn RODRIGUEZ, Jacqueline BURNELL, Sonia CERESO, Vanessa KERCHER, Jordan HILL, Richard HOLDEN, Malaz BOUSTANI

Indiana University, Bloomington, United States

P280 VR&R Trial: Interim Results on the Use of Virtual Reality to Support Caregiver Respite in Dementia Care

Presenter — Lora Appel

Vanessa GEITZ (1), Samantha LEWIS-FUNG (1), Sahil PATEL (2), Mattaya PALLETT (1, 3), Essete TESFAYE (1), Lora APPEL (1, 4, 2)

(1) University Health Network, Toronto, Canada, (2) York University, Toronto, Canada, (3) Humber Polytechnic, Toronto, Canada, (4) York University, Toronto

P345 Faster is Better: Modifiable Risk Factors for Alzheimer's Disease & Dementia in the ACTIVE Study

Presenter — Hyunkyu Lee

Karlene BALL (2), Henry MAHNCKE (1)

(1) Posit Science, , (2) UNIVERSITY OF ALABAMA AT BIRMINGHAM,

P393 Differential Cognitive Responses to Active and Sham rTMS Combined with Cognitive Training in Early Alzheimer's Disease

Presenter — Juyoun Lee

Inho LEE (2), Kun Ho KIM (3), Ae Young LEE (1)

(1) Department of Neurology, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of, (2) Department of Radiology, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of, (3) Department of Nuclear Medicine, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of

P500 Neural substrates generating a gamma frequency response to 40Hz GENUS light and sound stimulation

Presenter — Diane Chan

Diane CHAN (1, 2), Ute GEIGENMULLER (1), Monica ZHENG (1), Andrew BECKER (1), Erika RUIZ (1), Remi PHILIPS (1), Natalie HAHN (1), Aaron BOES (3, 4), Matthew HOWARD (3, 4), Eleonora MARCANTONI (5), Simon HANSLMAYR (5), Diego VIDAUURRE HENCHE (6, 7, 8), Emery BROWN (1, 9), Edward BOYDEN (1), Li-Huei TSAI (1)

(1) MIT, Cambridge, United States, (2) Alnylam, Cambridge, United States, (3) University of Iowa, Iowa City, United States, (4) Iowa Neuroscience Institute, Iowa City, United States, (5) Centre for Neurotechnology, Glasgow, United Kingdom, (6) Centre de Recerca Matemàtica, Barcelona, Spain, (7) University of Oxford, Oxford, United Kingdom, (8) Aarhus University, Aarhus, Denmark, (9) Massachusetts General Hospital, Boston, United States

P563 Augmented Exercise Interventions: Optimizing Response to Exercise Modalities for Cognitive Enhancement in Early AD

Presenter — Krista Lanctot

Julian SCHECTER (1), Yejin KANG (1), Sandra BLACK (1), Nathan HERRMANN (2), Sara MITCHELL (1), Susan MARZOLINI (3), Paul OH (3), Jennifer RABIN (1), Tarek RAJJI (4), Mark RAPOPORT (1), Walter SWARDFAGER (1), Mehreen SIDDIQUI (1), Kate SURVILLA (1), Damien GALLAGHER (1)

(1) Sunnybrook Research Institute, Toronto, Canada, (2) Department of Psychiatry, University of Toronto, Toronto, Canada, (3) KITE Research Institute, Toronto Rehabilitation Institute – University Health Network, Toronto, Canada, (4) Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United States

P571 Mood and Cognitive Outcomes of a Mindfulness Based Intervention in Veterans with Mild Cognitive Impairment: A Pilot Randomized Trial

Presenter — Heera Kamaraj

Heera KAMARAJ (1, 2), Kathy XIE (1, 2), Sarah HARER (1, 2), Brenna HAGAN (2), Meltem KARACA (3), Sofia ANGELINI (1), Brandon FRANK (1, 4), Andrew BUDSON (1, 4), Katherine TURK (1, 4)

(1) Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, United States, (2) Alzheimer's Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, United States, (3) Assumption University, Worcester, United States, (4) Alzheimer's Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, United States

P573 BRIGHT-Mind Study: A Prospective, Randomized Trial of Digital Cognitive Training Effects on Cognitive, Functional and Imaging Outcomes

Presenter — Robert John Schafer

Kevin MADORE (1), Kelly Hennigan MACNIVEN (2), John G. NADRA (3), Preston P. THAKRAL (4), P. Murali DORAISWAMY (5)

(1) Lumos Labs, Inc., San Francisco, United States, (2) Independent, San Francisco, United States, (3) Michigan State University, East Lansing, United States, (4) Department of Psychology, Smith College, Northampton, United States, (5) Duke University School of Medicine, Durham, United States

P585 Non-Pharmacological Interventions for Dementia Prevention in Cognitively Unimpaired Adults at Elevated Risk: A Scoping Review

Presenter — Julie Oomens

Dandi CHEN (1), Samira MABOUDIAN (1), Mai ABDELMOATY (2), Joyce CHONG (1), Jessica KIRKLAND CALDWELL (1)

(1) Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, (2) Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P708 Plasma Proteomics Identifies a Two-Signal Synaptic Preservation Signature Associated with Cognitive Benefit in the FINGER Trial

Presenter — Adrian Noriega De La Colina

Adrian NORIEGA DE LA COLINA (1, 2, 3), Arvid GOLLWITZER (1, 4), Anna MATTON (5), Francesca MANGIALASCHE (5), Li-Huei TSAI (6), Alina SALOMON (5, 7, 8), Tiia NGANDU (5, 7), Giovanni TRAVERSO (9, 2, 10, 11), Miia KIVIPELTO (12, 13)

(1) Broad Institute of MIT and Harvard, Cambridge, United States, (2) Massachusetts Institute of Technology, Cambridge, United States, (3) Brigham and Women's Hospital, Boston, United States, (4) Massachusetts Institute of Technology, Cambridge, United States, (5) Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden, (6) The Picower Institute for Learning and Memory, MIT, Cambridge, United States, (7) Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland, (8) FINGERS Brain Health Institute, Stockholm, Sweden, (9) Broad Institute of MIT and Harvard, Solna, Sweden, (10) Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Cambridge, United States, (11) Koch Institute for Integrative Cancer Research, MIT, Cambridge, United States, (12) Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, (13) FINGERS Brain Health Institute, Stockholm, United States

P715 Clinical and neural predictors of a tailored Speech and Language Therapy intervention for Italian individuals with Primary Progressive Aphasia

Presenter — Petronilla Battista

Gaia C. SANTI (1), Simona ARESTA (1), Allegra BENZINI (1), Roberta TOMASONI (1), Paola SANTACESARIA (1), Cinzia PALMIROTTA (1), Davide MONGELLI (1), Anna GILIOLI (2), Laura LUMACA (2), Silvia BASAIA (2), Annamaria RIVA (2), Elisa CANU (2), Massimo FILIPPI (2), Federica AGOSTA (2)

(1) 1. Laboratory of Neuropsychology, Istituti Clinici Scientifici Maugeri IRCCS, Institute of Bari, Bari, Italy, Bari, Italy, (2) 2. Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy

BIOMARKERS (CSF & PLASMA) (67)

P4 A diagnostic blood omics-biomarker for Alzheimer's disease informed by microglial single-cell transcriptomics: A pilot study

Presenter — Ornit Chiba-Falek

Michael LUTZ, Ornit CHIBA-FALEK

Duke University, Durham, United States

P13 Baseline Biomarker Profiles in the Diverse Vascular Contributions to Cognitive Impairment and Dementia (DVCID) Study

Presenter — Sitong (agnes) Zhou

Jacopo DI LUCENTE (1), Jacob CONSTON (1), Danielle HARVEY (1), Myriam FORNAGE (2), Charles DECARLI (1), Lee-Way JIN (1)

(1) University of California, Davis, Sacramento, United States, (2) UTHealth Houston School of Public Health, Houston, United States

P19 Plasma proteomic risk enrichment for incident all-cause dementia in UK Biobank: a five-protein score

Presenter — Simin Yang

Simin YANG, Yuqian YANG, Hongying DENG, Yao LIU, Zhuyong WANG, Jiajun ZHANG, Wangming ZHANG
Neurosurgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

P23 Temporal and Dose-Dependent Modulation of the Endocannabinoid System by Dual FAAH/MAGL Inhibition in Humans: Implications for Alzheimer's Disease

Presenter — Jie Li

Sumit BANSAL (2), Rui ZHAO (2), Joel SCHWARTZ (2), Rosa MICELI (2), Marc GLEICHMANN (2), Yongjun XUE (2), Mary COFFEY (2), Yi LUO (2), Sarah HARRIS (2)
(1) BMS, San Diego, United States, (2) BMS, Princeton, United States

P71 Reducing the P-tau217 Diagnostic Grey Zone Through Multimarker and Sequential Strategies Incorporating Plasma A β in Mild Cognitive Impairment

Presenter — María Pascual-Lucas

Leticia SARASA (1), Noelia FANDOS (1), Jorge LOSCOS (1), Judith ROMERO (1), Adrián SÁNCHEZ (1), Jose TERCICIO (2, 1), Isabel ORTEGA-MADUEÑO (3), María Cruz CÁRDENAS (3), Fernando CAVA-VALENCIANO (3), María José GIL-MORENO (4), Jordi A MATÍAS-GUIU (4), Jose Antonio ALLUÉ (1)
(1) Araclon Biotech-Grifols, Zaragoza, Spain, (2) Grifols, Barcelona, Spain, (3) Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain, (4) Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain

P89 Apolipoprotein E4 quantification by NULISA in cognitively unimpaired cohorts for screening for APOE ϵ 4 carriership and homozygosity

Presenter — Ashvini Keshavan

Ashvini KESHAVAN (1, 2), Katharine WILTSHIRE (1, 2), Amanda HESLEGRAVE (2), Henrik ZETTERBERG (2, 3), Jonathan SCHOTT (1, 2)
(1) Dementia Resarch Centre, UCL Queen Square Institute of Neurology, London, United Kingdom, (2) UK Dementia Research Institute at University College London, London, United Kingdom, (3) Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

P116 Using Digital Twins to Improve Statistical Efficiency in Alzheimer's Disease Trials with p-tau217

Presenter — Anoop Praturu

Anoop PRATURU, Coco KUSIAK
Unlearn AI, San Francisco, United States

P120 Real-World Adoption of Blood Biomarkers to Support Timely Diagnosis of Alzheimer's Disease: Ongoing Multinational Implementation Study

Presenter — Amy Deckert

Monica ZIGMAN SUCHSLAND, Karen WEYRAUCH, Tim MACLEOD, Katherine J. SELZLER, Alissa KURZMAN, Amy DECKERT
Davos Alzheimer's Collaborative, Wayne, United States

P124 Development of a plasma biomarker signature for Alzheimer's disease using the Roche NTK; what do we gain by adding to pTau217?

Presenter — Rodrigo Canovás

Rodrigo CANOVÁS (1), Azadeh FEIZPOUR (2, 3), Christopher J. FOWLER (2), Vincent DÓRE (1, 3), Gwendlyn KOLLMORGEN (4), Clara QUIJANO-RUBIO (5), Christopher M. RANK (4), Simon M. LAWS (6, 7, 8), Larry WARD (2), Colin L. MASTERS (9), Christopher C. ROWE (2, 3), James D. DOECKE (6, 10)
(1) The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia, (2) The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Melbourne, Victoria, Australia, (3) Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia, (4) Roche Diagnostics GmbH, Penzberg, Germany, (5) Roche Diagnostics International Ltd, Rotkreuz, Switzerland, (6) Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia, (7) Collaborative Genomics and Translation Group, Edith Cowan University, Joondalup, Western Australia, Australia, (8) Curtin Medical School, Curtin University, Bentley, Western Australia, Australia, (9) Alzheimer's Research Australia, The University of Western Australia, Western Australia, Australia, (10) The Australian e-Health Research Centre, CSIRO, Brisbane, Australia

P127 Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab

Presenter — Jie Janice Pan

Simon ROTHWELL (1), Daniela ROSSI (1), Jo VANDERCAPPELLEN (3), Cianne PARK (4), Indeg SLY (4)

(1) Eisai Europe LTD, Hatfield, United Kingdom, (2) Eisai Inc, Nutley, New Jersey, United States, (3) Eisai Pharma AG, Zurich, Switzerland, (4) Acumetis, London, United Kingdom

P132 Association of HDL Cholesterol With Longitudinal Brain Tau Deposition: A Cross-Ethnic Cohort Study

Presenter — Jee Wook Kim

Hye Ji I CHO (1), Shin Gyeom KIM (2), Dong Young LEE (3)

(1) Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, (2) Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of, (3) Seoul National University Hospital, Seoul, Korea, Republic of

P147 Optimization of a Rapid, Cost-Effective qPCR Assay for Apolipoprotein E Genotyping

Presenter — Lauren Johnson

Sarah AUGUSTE MCCAULLEY (1), Isabelle PHILIPP (1), Zuguang WANG (1), Matthew STICCO (2), Logan VERO (2), Kavita JAIN (2), Ganesan ANTHONY (2), Arejas UZGIRIS (1)

(1) Siemens Healthcare Diagnostics, East Walpole, United States, (2) Siemens Healthcare Diagnostics, Tarrytown, United States

P154 Brain-enriched Circular RNAs as blood-based biomarkers for detection of Alzheimer's disease-related biology across the disease continuum

Presenter — Nikolaos Mellios

Bridget PHILLIPS (2), Sanford JESSIE (2), Janve VAIBHAV (3), Mellios NIKOLAOS (1), Papageorgiou GRIGORIOS (1), Morris JOHN (2), Perlmutter JOEL (2), Kotzbauer PAUL (2), Perrin RICHARD (2), Hohman TIMOTHY (3), Ibanez LAURA (2), Cruchaga CARLOS (2)

(1) Circular Genomics, San Diego, United States, (2) Washington University School of Medicine, St Louis, United States, (3) Vanderbilt University Medical Center, Nashville, United States

P156 Toward an inflammation axis for the ATN(V)I framework in dementia: CSF outperforms plasma and MRI biomarkers using the albumin index as a standard for inflammation

Presenter — Gary Rosenberg

Azadeh GOLDUZIAN, Erik ERHARDT, Atvind CAPRIHAN, John ADAIR, Jsniice KNOEFEL, Jill PRESTOPNICK, Sasha HOBSON, Gary ROSENBERG

University of New Mexico, Albuquerque, United States

P157 Healthcare Provider Perspectives and Confidence in Using Alzheimer's Blood Biomarkers in Clinical Practice

Presenter — Amy Deckert

Monica ZIGMAN SUCHSLAND, Karen WEYRAUCH, Katherine SELZLER, Tim MACLEOD, Alissa KURZMAN, Amy DECKERT

Davos Alzheimer's Collaborative, Wayne, United States

P163 Prediction of Amyloid Positivity Using Historical EMR-Derived CBC and Chemistry Data

Presenter — Amir Glik

Amir GLIK (1, 2, 3, 4), Boaz CITRIN (1, 2), Marianna ABAJYAN (1, 2), Hayim RACLAW (1, 2), Gal AVIRAM (1, 2)

(1) ALZAI Health Corp., Toronto, Canada, (2) ALZAI Health Israel Ltd, Givatayim, Israel, (3) Cognitive Neurology Clinic, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, (4) Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

P187 Use of the VeraBIND Tau Functional Plasma Assay to Detect Active Tau Pathology in Preclinical Mouse Models

Presenter — Nicole M Maphis

Nicole M MAPHIS (1, 2), Joshua SOLDO (3), Kavya SHAMSUNDAR (3), Winnie PAK (3), Khalid IQBAL (4, 5), Ali RIAZI (2), Kiran BHASKAR (1, 2)

(1) Department of Molecular Genetics & Microbiology/Neurology, University of New Mexico, Albuquerque, United States, (2) TheraVac Biologics, Albuquerque, United States, (3) Veravas, Inc, Austin, United States, (4) New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States, (5) Phanes Biotech, Inc, Malvern, United States

P193 Real-World Plasma Alzheimer Biomarkers, Amyloid PET, and Functional–Cognitive Burden in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenter — Hanan Sheikh Ibrahim,md,facp

¹ Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates ² Center for Continuing Medical Learning (CCLM), Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, United Arab Emirates

P196 Real-World Plasma Neurofilament Light Chain, Functional Staging Severity, and Amyloid PET Non-Concordance in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenter — Hanan Sheikh Ibrahim,md,facp

Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates ² Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, United Arab Emirates

P234 Diagnostic accuracy of Elecsys pTau181 and pTau217 plasma assays using global cutoffs in an Asian cohort: Results from the K-ROAD registry

Presenter — Jun Pyo Kim

Gwendlyn KOLLMORGEN (2), Christian KUFFER (2), Annunziata DI DOMENICO (3), Myrto ANDREADOU (3), Tobias BITTNER (4, 5), Sayuri HORTSCH (2), Sang Won SEO (1)

(1) Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, (2) Roche Diagnostics GmbH, Penzberg, Germany, (3) Roche Diagnostics International Ltd, Rotkreuz, Switzerland, (4) F. Hoffmann-La Roche Ltd, Basel, Switzerland, (5) Genentech, Inc., South San Francisco, United States

P236 Factors influencing longitudinal plasma phospho-tau 217 and 181 changes in Alzheimer’s dementia – a memory clinic follow-up study.

Presenter — Michaela Defrancesco

Michaela DEFRANCESCO, Christian HUMPEL

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P240 The associations between plasma-based synaptic, neurodegeneration, vascular, and inflammatory biomarkers with synaptic density in neurodegeneration measured using [18F]SynVesT-1 PET.

Presenter — Koen Poesen

Soha ALALI (1), Charles CARRON (1), Amir GHODRATI (1), Susanne SCHMIDT (2), Koen VAN LAERE (1)

(1) KU Leuven, Leuven, Belgium, (2) UBonn, Bonn, Germany

P251 Amyloid Pathology Modulates the Proteomic Architecture of Global Cognition

Presenter — Sokratis Charisis

Vasiliki Amaryllis SKYFA (1, 2), Christopher PAPANDREOU (1), Martina SAMIOTAKI (3), Georgios HADJIGEORGIOU (4), Efthimios DARDIOTIS (5), Mary H. KOSMIDIS (6), Mary YANNAKOULIA (7), Paraskevi SAKKA (8), Archontoula DROUKA (7), Dora BRIKOU (7), Eirini MAMALAKI (7), Eva NTANASI (2), Nikolaos SCARMEAS (2), Athos ANTONIADES (10)

(1) Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Greece, (2) First Department of Neurology, Aiginion Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, (3) Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece, (4) Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus, (5) Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, (6) Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece, (7) Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, (8) Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece, (9) Harvard Medical School & Massachusetts General Hospital, Boston, United States, (10) Stremble Ventures LTD, Limassol, Cyprus

P254 Domain-Specific CSF Proteomic Signatures of Cognitive Function in the ALBION Cohort

Presenter — Sokratis Charisis

Vasiliki Amaryllis SKYFA (1, 2), Christopher PAPANDREOU (1), Martina SAMIOTAKI (3), Georgios HADJIGEORGIOU (4), Efthimios DARDIOTIS (5), Mary H. KOSMIDIS (6), Mary YANNAKOULIA (7), Paraskevi SAKKA (8), Archontoula DROUKA (7), Dora BRIKOU (7), Eirini MAMALAKI (7), Eva NTANASI (2), Nikolaos SCARMEAS (2), George MANIAS (10)

(1) Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Greece, (2) First Department of Neurology, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, (3) Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece, (4) Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus, (5) Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, (6) Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece, (7) Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, (8) Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece, (9) Harvard Medical School & Massachusetts General Hospital, Boston, United States, (10) Department of Digital Systems, University of Piraeus, Piraeus, Greece

P256 Development and Analytical Validation of a Plasma ELISA for Glial Fibrillary Acidic Protein (GFAP) and Exploratory Analysis in a Clinical Cohort of Patients with Alzheimer's disease

Presenter — Noelia Fandos

Raquel RODRÍGUEZ (1), Judith ROMERO (1), María PASCUAL-LUCAS (1), José Antonio ALLUÉ (1), Leticia SARASA (1), Jesús CANUDAS (1), Ignacio MARTÍNEZ (1), María MONTAÑÉS (1), Jose TERENCIO (2, 1), Jorge LOSCOS (1)

(1) Araclon Biotech, Zaragoza, Spain, (2) Grifols, Sant Cugat Del Vallès, Barcelona, Spain

P290 BD-p-Tau217/BD-p-Tau181 Tasso+ Capillary Plasma Ratio Best Correlates with Venous Plasma p-Tau217

Presenter — Taraneh Atri

Marisa N. DENKINGER (1), James LIU (1), Alpana SINGH (1), Michelle SURDYN (1), Victoria BROWN (1), Guadalupe MARTINEZ (1), Angela KURAMOTO (1), Taina M. MARQUES (1), Jessica B. LANGBAUM (2), Alireza ATRI (1), Nicholas J. ASHTON (1)

(1) Banner Sun Health Research Institute, Sun City, United States, (2) Banner Alzheimer's Institute, Phoenix, United States

P301 pTau-217 in Clinical Practice: Utilization Patterns and APOE-Driven Variability in Real-World Data

Presenter — Joseph Volpe

David ALFEGO (1)

(1) Labcorp, San Diego, United States, (2) Labcorp, Durham, United States

P311 Circular RNA Blood-Based Biomarkers Reliably Predict Progression of Asymptomatic Individuals to Alzheimer's Disease: ADRC and A4/LEARN Cohort Replication

Presenter — Dehart Jessica

Bridget PHILLIPS (1), Sanford JESSIE (1), Janve VAIBHAV (2), Mellios NIKOLAOS (3), Papageorgiou GRIGORIOS (3), Morris JOHN (1), Perlmutter JOEL (1), Kotzbauer PAUL (1), Perrin RICHARD (1), Hohman TIMOTHY (2), Ibanez LAURA (1), Cruchaga CARLOS (1)

(1) Washington University School of Medicine, St. Louis, United States, (2) Vanderbilt University Medical Center, Nashville, United States, (3) Circular Genomics, San Diego, United States

P313 Alzheimer's Disease specificity and consistent performance of a Circular RNA Blood-Based Biomarker Model Across Diverse Populations

Presenter — Dehart Jessica

Bridget PHILLIPS (1), Sanford JESSIE (1), Janve VAIBHAV (2), Mellios NIKOLAOS (3), Papageorgiou GRIGORIOS (3), Morris JOHN (1), Perlmutter JOEL (1), Kotzbauer PAUL (1), Perrin RICHARD (1), Hohman TIMOTHY (2), Ibanez LAURA (1), Cruchaga CARLOS (1)

(1) Washington University School of Medicine, St. Louis, United States, (2) Vanderbilt University Medical Center, Nashville, United States, (3) Circular Genomics, San Diego, United States

P315 Circular RNA Biomarkers for Alzheimer's Disease are Associated with Multi-Lineage Pathological Pathways and significantly enriched in the brain

Presenter — Mellios Nikolaos

Papageorgiou GRIGORIOS (1), Phillips BRIDGET (2), Cruchaga CARLOS (2)

(1) Circular Genomics, San Diego, United States, (2) Washington University School of Medicine, St. Louis, United States

P317 Blood-Based Circular RNA Biomarkers for Alzheimer's Disease: Analytical Performance Using circRNA-specific quantitative and digital droplet PCR

Presenter — Mellios Nikolaos

Papageorgiou GRIGORIOS (1), Phillips BRIDGET (2), Cruchaga CARLOS (2)

(1) Circular Genomics, San Diego, United States, (2) Washington University School of Medicine, St. Louis, United States

P327 From Stackers to Streamliners: Alzheimer's Disease Work-up Archetypes and the Impact of AD BBM Ratio Test Results on Diagnostic Escalation

Presenter — Lopamudra Das

Trevar BURGON (1), David PACULDO (1)

(1) QURE Healthcare, St. Louis, United States, (2) Beckman Coulter Diagnostics, Brea, United States

P344 Needle-free biomarker detection platform using the olfactory neuroepithelium: superiority to blood-based assays in Alzheimer's disease

Presenter — Koko Ishizuka

Koko ISHIZUKA, Guanqun SHANG, Akira SAWA

Johns Hopkins University, Baltimore, United States

P347 Blood CD8 T cell recognition of APP and derivative non-A β peptides as screenable biomarkers for Alzheimer's and related MCI

Presenter — Christopher Wheeler

Christopher WHEELER (1, 2, 3, 4), Pénélope BOURGOIN (5), Debby VAN DAM (6, 7), Yannick VERMEIREN (8, 9), Hans DE REU (9), Peter Paul DE DEYN (6, 7), Jean-Marc BUSNEL (5)

(1) T-NeuroDx; Ortega NeuroTherapeutics, Albuquerque, Aptos, United States, (2) Society for Brain Mapping & Therapeutics, World Brain Mapping Foundation, Los Angeles, United States, (3) StemVax LLC, a wholly owned subsidiary of NovAccess Global, Cleveland, United States, (4) Dept of Chemistry & Biochemistry, University of California, Santa Cruz, Santa Cruz, United States, (5) Beckman-Coulter Life Sciences, Marseille, France, (6) Dept of Biomedical Sciences, Institute Born-Bunge, Laboratory of Neurochemistry and Behavior, University of Antwerp, Antwerp, Belgium, (7) Dept of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands, (8) Department of Biomedical Sciences, Institute Born-Bunge, Laboratory of Neurochemistry and Behavior, University of Antwerp, Antwerp, Belgium, (9) Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium

P349 A 5-Plex Plasma Biomarker Panel for Amyloid PET Status Classification Beyond pTau-217 Alone: A Pilot Study

Presenter — Noah Elder

Noah ELDER, Hien NGUYEN, Jason WAN, Robert LIN

Taudia, Inc., San Carlos, United States

P353 Inflection-based ordering of plasma and PET biomarkers along an Alzheimer's disease progression axis in two independent cohorts

Presenter — Jeon So Yeon

Lee KYUNGSUNG (1), Yi DAHYUN (2), Ham HYUNSUN (3), Byun MIN SOO (4, 5), Kim YU KYEONG (6, 7), Lee JUN-YOUNG (3, 4), Lee DONG YOUNG (4, 5), Jeon SO YEON (3, 4)

(1) Emocog, Seoul, Korea, Republic of, (2) Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea, Republic of, (3) Department of Psychiatry, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of, (4) Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea, Republic of, (5) Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea, Republic of, (6) Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, (7) Department of Nuclear Medicine, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of

P356 Antemortem α -Synuclein levels from neuron-derived extracellular vesicles identify Lewy Body co-pathology in Alzheimer Disease and Parkinson's Disease

Presenter — Badri Vardarajan

Tamil GUNASEKARAN (1), Dolly REYES-DUMEYER (1), Yian GU (1), Olga VOLPERT (2), Lawrence HONIG (1), Richard MAYEUX (1), Erez EITAN (2)

(1) Columbia University, New York, United States, (2) Neurodex, Natick, United States

P363 A Novel Plasma Biomarker Panel Assessed by NULISA Improves Amyloid Positivity Diagnosis Beyond pTau-217 for Clinical Trial Enrichment

Presenter — Ser Mien Chia

Yumi KAWAMURA (1), Geetha CHILLA (1), Nicholas HO (1), Charlene ONG (1), Matthew CHOO (1), Ryan CLARK (2), Dean LEE (1), Asad ABU BAKAR ALI (1), Matthew KENNEDY (2)

(1) Quantitative Biosciences, MSD International GmbH, Singapore, Singapore, Singapore, (2) Discovery Neuroscience, Merck & Co., Inc., Boston, MA, USA, Boston, United States

P370 Brain Mass Spectrometry-Guided Development of Novel Plasma Immunoassays for Early Tau Pathology

Presenter — Xuemei Zeng

Marissa FARINAS (1), Lamia T CHOITY (1), Eric E ABRAHAMSON (1), Milos D IKONOMOVIC (1), Alexandra J GILSRUD (1), Monika R SANOTRA (1), Julia K KOFLEER (1), Beth E SNITZ (1), Annie D COHEN (1), Oscar L LOPEZ (1), Lei LIU (2), Jasmeer P CHHATWAL (2), Thomas K KARIKARI (1)

(1) University of Pittsburgh, Pittsburgh, Pa, United States, (2) Harvard University, Cambridge, Ma, United States

P375 Ratio-Based Plasma p-Tau217 Biomarkers Outperform Single Measures for Detecting Early Amyloid Pathology in Preclinical AD

Presenter — James D Doecke

James D DOECKE (1, 2), Azadeh FEIZPOUR (3, 4), Rodrigo CANOVAS (1), Christopher J FOWLER (3), Simon LAWS (2), Larry WARD (3), Colin L MASTERS (5), Ruth PFEIFFER (6), Corey CARLSON (6), Jeremiah S HINSON (7), Charbel ABOU-DIWAN (6), Ruth PFEIFFER (6), Christopher C ROWE (3, 4), Vincent DORE (8, 4)

(1) Australian E-Health Research Centre, CSIRO, Herston, Australia, (2) Centre for Precision Health, Edith Cowan University, Joondalup, Australia, (3) The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, (4) Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia, (5) Alzheimer's Research Australia, University of Western Australia, Nedlands, Australia, (6) Beckman Coulter Diagnostics, Brea, United States, (7) Danaher Diagnostics, Washington, United States, (8) Australian E-Health Research Centre, CSIRO, Parkville, Australia

P380 Plasma p-Tau217 as a Diagnostic and Prognostic Biomarker of Alzheimer's Disease in Mild Cognitive Impairment: Associations with Dementia Progression and Longitudinal Cognitive Decline in a Real-World Cohort

Presenter — Guido Maria Giuffrè

Guido Maria GIUFFRÈ, Davide QUARANTA, Domenico FUSCO, Maria GISTRO, Naïke CARAGLIA, Cinzia CARROZZA, Paolo CALABRESI, Camillo MARRA

Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy

P385 Synaptic blood marker β -synuclein decreases within 6 months of lecanemab treatment and predicts amyloid clearance

Presenter — Patrick Oeckl

Patrick OECKL (1, 2), Tara ELLINGSON (3), Argentina LARIO LAGO (3), Julio C. ROJAS (3), Lawren VANDEVREDE (3), Markus OTTO (4)

(1) German Center for Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany, (2) Ulm University Hospital, Department of Neurology, Ulm, Germany, (3) Edward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, United States, (4) Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (saale), Germany

P404 Mitigating amyloid endpoint heterogeneity to establish robust cutoffs and clinical performance of Elecsys pTau217 and pTau181 plasma immunoassays

Presenter — Sayuri Hortsch

Annunziata DI DOMENICO (2), Myrto ANDREADOU (2), Imke KIRSTE (3), Michael WEINER (4), Christopher ROWE (5, 6), James DOECKE (7, 8), Niklas MATTSSON-CARLGREN (9, 10), Sebastian PALMQVIST (9, 10), Gregory KLEIN (11), Tobias BITTNER (11, 12)

(1) Roche Diagnostics GmbH, Penzberg, Germany, (2) Roche Diagnostics International Ltd, Rotkreuz, Switzerland, (3) Roche Molecular Systems Inc, Tucson, United States, (4) University of California San Francisco, San Francisco, United States, (5) Australian Dementia Network, University of Melbourne, Melbourne, Australia, (6) Austin Health, Melbourne, Australia, (7) Australian E-Health Research Centre, CSIRO, Brisbane, Australia, (8) Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, (9) Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund

P422 Validation of Elecsys pTau217 plasma assay cutoffs for detection of amyloid pathology across care settings

Presenter — Annunziata Di Domenico

Sayuri HORTSCH (2), David CALEY (3), Niels BORLINGHAUS (2), Kaj BLENNOW (4, 5), Oskar HANSSON (5, 6), Marc SUÁREZ-CALVET (7, 8), Craig RITCHIE (9), Nicholas ASHTON (10, 11), Marisa DENKINGER (11), Christopher ROWE (12, 13), Ming LU (14), Sameera WIJAYAWARDANA (15), Sebastian PALMQVIST (6, 16)

(1) Roche Diagnostics International Ltd, Rotkreuz, Switzerland, (2) Roche Diagnostics GmbH, Penzberg, Germany, (3) Roche Diagnostics Ltd, Burgess Hill, United Kingdom, (4) Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, (5) Eli Lilly and Company, Stockholm, Sweden, (6) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, (7) Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, (8) Servei de Neurologia, Hospital del Mar, Barcelona, Spain, (9) Scottish Brain Sciences, Edinburgh, United Kingdom, (10) Banner Alzheimer's Institute and University of Arizona, Phoenix, United States, (11) Banner Sun Health Research Institute, Sun City, United States, (12) Australian Dementia Network Ltd, Melbourne, Australia, (13) University of Melbourne, Melbourne, Australia, (14) Eli Lilly and Company, Philadelphia, United States, (15) Eli Lilly and Company, Indianapolis, United States, (16) Memory Clinic, Skåne University Hospital, Malmö, Sweden

P423 Inflammatory Biomarkers in Alzheimer's Disease Immunomodulatory Trials: A Systematic Review of Biomarker–Clinical Concordance and Translational Context-of-Use

Presenter — Myuri Ruthirakuhan

Nicole OWSICKI (1), Sofia PERFETTO (1), Kiran SHOCKER (1), Amanda LEISGANG OSSE (2), Yadi ZHOU (3), Min Su KANG (1), Feixiong CHENG (3), Walter SWARDFAGER (1), Jeffrey CUMMINGS (2), Julie OTTOY (1, 4)

(1) Sunnybrook Research Institute, Toronto, On, Canada, (2) Department of Brain Health, University of Nevada Las Vegas, Las Vegas, United States, (3) Cleveland Clinic, Las Vegas, United States, (4) Department of Medicine (Neurology), University of Toronto, Toronto, On, Canada

P424 Quantum Capacitance Electrochemical Biosensor for the Rapid and Ultrasensitive Detection of p-tau217 and MTBR-tau243

Presenter — Dishit P. Ghumra

Keyao SONG (1), Spondita GOSWAMI (2), Rajan K. CHAKRABARTY (1)

(1) Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, United States, (2) Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, United States

P439 Longitudinal Analysis of Circulating microRNA Expression Patterns During Alzheimer's Disease

Presenter — Simran Yadav

Aida MUNTSANT-SORIA (2), Lydia GIMÉNEZ-LLORT (2), Urszula WOJDA (1)

(1) Laboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland, Warszawa, Poland, (2) Institut de Neurociències, Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain., Spain, Poland

P450 Plasma brain-derived p-tau217/total-tau ratio outperforms plasma p-tau217 for detecting autopsy-confirmed Alzheimer's neuropathology, including in early-disease and mixed-pathology cases

Presenter — Denis Smirnov

Denis SMIRNOV (1, 2), Xuemei ZENG (3), Marissa FARINAS (3), Michel NAFASH (3), Victor VILLEMAGNE (3), Sarah BERMAN (3), Henrik ZETTERBERG (4), Tharick PASCOAL (3), Beth SNITZ (3), Ann COHEN (3), Oscar LOPEZ (3), M. Ilyas KAMBOH (3), Milos IKONOMOVIC (3), Julia KOFLER (3), Thomas KARIKARI (3)

(1) Mass General Brigham, Boston, United States, (2) Harvard Medical School, Boston, United States, (3) University of Pittsburgh, Pittsburgh, United States, (4) University College London, London, United States

P453 US Real-World Patterns of Amyloid Testing and Anti-Amyloid Therapy Initiation in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI)

Presenter — Kinyee Fong

Ameur M. MANCEUR (2), Nick BELVISO (1), Eli SHOBIN (1), Boyang BIAN (1), Akash BHUSHAN (3), Lisa LEUNG (3), Adyasha DAS (3), Sonick SURI (3), Vamsi Chandra KASIVAJJALA (3), Lydia WOOD (1)

(1) Biogen MA Inc., Cambridge, United States, (2) Cytel, Cambridge, United States, (3) NeuroDiscovery AI, Alpharetta, United States

P460 Single-aggregate detection of misfolded neurodegenerative disease proteins

Presenter — Andrew Stern

Chungmin HAN (2), Borberg ELLA (2), Lily WICKLAND SHEARER (1), Tal GILBOA (2), Zoe SWANK (2), Arek MELKONIAN (2), Justin ROLANDO (2), David WALT (2)

(1) Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Department of Neurology, Boston, United States, (2) Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, United States

P463 Comparing results from three Alzheimer's Disease plasma biomarker tests in a prescreen study in healthy elderly participants

Presenter — Lydia Morris

Lev GERTSIK (1), Svetlana SEMENOVA (2), Gary WALKER (3), Aaron KOENIG (3)

(1) California Clinical Trials Medical Group, Glendale, United States, (2) Parexel International, Glendale, United States, (3) Syndeio Biosciences, Indianapolis, United States

P480 Enhanced Discrimination of Parkinson's Disease Using a Novel α -Synuclein Signature Assay on the SPEAR Platform

Presenter — Tracy Liu

Erden EREN, Jeremy TAN, Emma TORDOFF, Tucker FONTANA, Tsz Wing FAN, Feng XUAN, Tracy LIU

Spear Bio, Woburn, United States

P489 Improved Stratification of Parkinson's Disease Using a Novel Ratio Analysis of Total and pS129- α -Synuclein Enabled by the SPEAR Platform

Presenter — Tracy Liu

Jeremy TAN, Emma TORDOFF, Erden EREN, Tucker FONTANA, Tsz Wing FAN, Tracy LIU, Xue FENG

Spear Bio, Woburn, United States

P498 Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer's Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217

Presenter — Samantha Friend

Bryan DIRKS (2), Becky HOWELL (2), Xiaoshu FENG (2), Sanjeev PATHAK (2)

(1) Acadia Pharmaceuticals Inc., San Diego, United States, (2) Acadia Pharmaceuticals Inc., Princeton, United States

P506 A Novel 5-Plex SPEAR Assay Targeting BD-pTau 217, eMTBR-Tau, BD-Tau, NF-L and GFAP Enables Comprehensive Assessment of Alzheimer's Disease Pathology and Neurodegeneration

Presenter — Tracy Liu

Ahsan AUSAF ALI, Jiachong CHU, Pengyu HAO, Xi CHEN, Arian PUSHKA, Chi TANG, Zidong WANG, Tracy LIU, Feng XUAN

Spear Bio, Woburn, United States

P522 Blood-Based and Digital Biomarker Strategies Are Reshaping Alzheimer's Clinical Trial Recruitment, Cohort Readiness, and Site Operations

Presenter — Sean Stanton

Sean STANTON, Candice ESPINOZA, Sameer SIDDIQUI, Taylor RICE, Brandon LENOX, Briana STANTON

K2 Medical Research, Maitland, FL, United States

P556 Association of plasma p-tau217 with [18F]flortaucipir and [18F]MK-6240 across the Alzheimer's disease continuum: a head-to-head within subject comparison

Presenter — Pamela C L Ferreira

Guilherme POVALA (1), Bruna BELLAVER (1), Joseph C. MASDEU (2), Juan FORTEA (3), Dana L. TUDORASCU (1), Thomas K. KARIKARI (1), Hwamee OH (4), Val LOWE (5), David N. SOLEIMANI-MEIGOONI (6), Brian A. GORDON (7), Belen PASCUAL (2), Pedro ROSA-NETO (8), Suzanne BAKER (6), Tharick A. PASCOAL (1)

(1) University of Pittsburgh, Department of Psychiatry, Pittsburgh, United States, (2) Houston Methodist Research Institute, Department of Neurology, Houston, United States, (3) Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (4) Brown University, Department of Psychiatry and Human Behavior, Providence, United States, (5) Mayo Clinic, Department of Radiology, Rochester, United States, (6) Lawrence Berkeley National Laboratory, Berkeley, United States, (7) Washington University in St. Louis, Department of Radiology, St. Louis, United States, (8) Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute, Montréal, United States

P561 A Clinically Tractable Five-protein Plasma Panel Improves Alzheimer's Disease Diagnosis Beyond p-Tau217

Presenter — Johannes Eichner

Scott LEVIN (2), Muhammad ALI (3), Carlos CRUCHAGA (3), Timo WITTENBERGER (1), Jeremiah HINSON (2)

(1) Genedata, Basel, Switzerland, (2) Danaher Diagnostics, Washington, Dc, United States, (3) Washington University, Saint Louis, Mo, United States

P589 Analytical Validation of a novel liquid chromatography–tandem mass spectrometry (LC-MS/MS) multiplexed method measuring three phosphorylated forms of tau protein in plasma for Research Use.

Presenter — Venky Venkatesh

Matthew MEYER, Xiping LIU, Faith IRVIN, Mark ADAMS, Tim WEST, Venky VENKATESH, John BUI, Justine COPPINGER, Philip VERGHESE

C2N Diganostics, LLC, Saint Louis, United States

P595 Performance of Plasma and CSF biomarkers for tauPET staging in Alzheimer's Disease: evidence from mass spectrometry and immunoassays in Autonomy

Presenter — Shannon Leslie

Tina WANG (1), Setareh MOUGHADAM (1), Fatma AYHAN (2), Stephanie SLANIA (2), Kristof VAN KOLEN (3), Ziad SAAD (1), Gallen TRIANA-BALTZER (1)

(1) Johnson & Johnson, San Diego, United States, (2) Johnson & Johnson, Springhouse, United States, (3) Johnson & Johnson, Beerse, Belgium

P625 From Bench to Bedside: Presynaptic Complexins as Synaptic Endpoints for Alzheimer's Disease Trials

Presenter — Ted Wilson

Justin H. MENDIOLA (1), Sophie JONES (1), Masood MANOOCHERHI (1), Bess FROST (1), Edward HUEY (2)

(1) Brown University, Providence, United States, (2) Butler Hospital, Providence, United States

P644 Plasma and Tau-PET Reflect Distinct Biological Processes Underlying Cognitive Decline in Alzheimer's Disease

Presenter — James D Doecke

James D DOECKE (1, 2), Azadeh FEIZPOUR (3, 4), Rodrigo CANOVAS (5), Christopher J FOWLER (3), Jurgen FRIPP (1), Simon LAWS (2, 6), Larry WARD (3), Colin L MASTERS (7), Paul MARUFF (8), Corey M CARLSON (9), Jeremiah S HINSON (10), Charbel ABOU-DIWAN (9), Ruth PFEIFFER (9), Christopher C ROWE (3, 4), Vincent DORE (5)

(1) The Australian e-Health Research Centre, CSIRO, Herston, Australia, (2) Centre for Precision Health, Edith Cowan University, Joondalup, Australia, (3) The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, (4) Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia, (5) The Australian e-Health Research Centre, CSIRO, Parkville, Australia, (6) Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, (7) Alzheimer's Research Australia, University of Western Australia, Nedlands, Australia, (8) Cogstate, Ltd, Parkville, Australia, (9) Beckman Coulter Diagnostics, Chaska, United States, (10) Danaher Diagnostics, Washington, United States

P656 Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health

Presenter — Shawn Kile

Shawn KILE, Armen MOUGHAMIAN, Kimberly CHRISTENSEN, Tammy DONNEL, Sarah ROBINSON, Katherine GILLESPIE, Gregory TRANAH

Sutter Health Research Institute, San Francisco, United States

P669 Impact of Blood-Based Biomarkers (BBMs) on Time to Treatment Initiation with Anti-Amyloid Therapies (AATs): A Retrospective Analysis Using the Optum Market Clarity Alzheimer's Enriched Data

Presenter — Rifky Tkatch

Courtney ADAMS (1), Bryan COBB (1), Feride FRECH (1), Bonnie BUI (2), Jamie TUCKER (2), Brady DEHART (2), Julia CERTA (2), Hideki TOYOSAKI (2), Yosuke NAKAMURA (2), Rhonna SHATZ (3)

(1) Eisai Inc., Nutley, United States, (2) Optum Life Science, Eden Prairie, United States, (3) University of Cincinnati, Cincinnati, United States

P689 Foundation model-enabled multi-omic profiling for differential diagnosis of Alzheimer's disease and related dementias: discovery across AD, FTD and LBD with validation in a real-world NHS memory clinic cohort

Presenter — Hayley Holt

Carolina MACHADO (1), Anjeet JHUTTY (1), Christoforos NALMPANTIS (1), Pouya NIKI (1), Ravi SOLANKI (2), Georgia ROSS (1), Ivan KOYCHEV (1)

(1) Prima Mente, London, United Kingdom, (2) Prima Mente, San Francisco, United States

P698 Not a Substitute for Confirmation: The Performance of Commercial Plasma Biomarkers in a Real-World Anti-Amyloid Treatment Pathway

Presenter — Aaron Ritter

Stephanie MARTINS (1), Erica WELCH (1), Junko HARA (1), Jefferson KINNEY (2)

(1) Hoag Neuroscience Institute, Newport Beach, United States, (2) UNLV, Las Vegas, United States

P719 Astroglial Activation and Neurodegeneration as Kinetic Switches for p-Tau 217 Progression: A Longitudinal Multi-Analyte Stratification Analysis

Presenter — David Wilson

David WILSON, Lindsey METTE, Meenakshi KHARE, Matt POLACK, Jorge MARQUES

Quanterix, Billerica, United States

PRE-CLINICAL, EARLY DISCOVERY & MECHANISTIC RESEARCH ⁽²¹⁾

P3 A postmortem whole human brain platform for Alzheimer's disease drug discovery

Presenter — Paul Wes

Paul WES, Nghia NGUYEN, Congwei WANG, Scott POPE, Josip BUTKOVIC, Ivan MUMLEK, Chunmin GE, Leah ROSALES, Lindsay SLUPCZEWSKI, Lucija BARISIC, Brad PARRY, Sean MURPHY, Zvonimir VRSELJA

Bexorg, New Haven, United States

P5 Translating single-cell multi-omics discoveries into APOE-targeted epigenome therapy for Alzheimer's Disease

Presenter — Ornit Chiba-Falek

Bernadette O'DONOVAN (1), Keats SHWAB (1), Boris KANTOR (2)

(1) Duke University, Durham, United States, (2) FSU, Durham, United States

P7 Synergistic Effects of Mild Behavioral Impairment and APOE ϵ 4 on Cognitive Function in a Community-Based Middle-Aged and Older Population

Presenter — Cheng-Sheng Chen

Cheng-Sheng CHEN, Yi-Chun YEH, Hsiu-Fen LIN

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

P17 next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenter — Jean-Philippe Courade

Nadia ANCERIZ (2), Roman RÖSEMANN (3), Pauline LLOVERAS (2), Laurence CHATEL (2), Bruno DAUBEUF (2), Alizée VIANDIER (2), Adeline LESNIER (2), Eric HATTERER (2), Oleg DEMIN JR (4), Dmitry SHCHELOKOV (4), Galina SAYNUKOVA (4), Nicolas PRADEILLES (5), Sylvain LEHMANN (5)

(1) discoveric bio alpha, Pfäffikon, Switzerland, (2) light chain biosciences, Plan Les Ouates, Switzerland, (3) granzer, Muenchen, Germany, (4) Insysbio, Paphos, Cyprus, (5) Laboratoire de Biochimie Protéomique Clinique CHU Montpellier, Montpellier, France

P25 Design and characterization of KRSA-028, a novel bispecific antibody targeting amyloid beta and transferrin receptor with selective effector function modulation

Presenter — Maribel Reyes

Bernard LIU (2), Melissa CONERLY (2), Kevin J. KRAMER (2), Kalyan PANDE (2), Erin CLARK (3), Alexander A. MITKAS (2), Russell SANDERSON (3), Joana VIDAL (2), Byron H. KWAN (2), Ghassan N. FAYAD (2), Jennifer SAGER (1), Jason OH (2), Michael MEEHL (2), Angela SHE (1)

(1) Korsana Biosciences, Waltham, Ma, United States, (2) Paragon Therapeutics, Waltham, Ma, United States, (3) Formerly of Paragon Therapeutics, Waltham, Ma, United States

P45 How Re:Cognition Health (RCH) has Fast Tracked Patients to Receive Amyloid Targeted Treatment (ATT)

Presenter — Macsweeney Emer

George ROBINSON (1), Penny MUIR (2)

(1) Doctor, London, United Kingdom, (2) EA, London, United Kingdom

P47 Polygenic risk score-based frailty index predicts conversion to tau-positivity in Alzheimer's disease

Presenter — Mi-Young Oh

Sang-Hyuk JUNG (2)

(1) Department of Neurology, Sejong General Hospital, Bucheon-Si, Korea, Republic of, (2) Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Korea, Republic of

P109 Alzheimer's Disease Patient Biology in a Dish

Presenter — Tetsuya Tanaka

Tetsuya TANAKA, Yasaman ANZABI

Ricoh Biosciences, Baltimore, United States

P188 Preclinical Validation of VGF-Derived Peptide TLQP-21 as an Intranasal Therapeutic in the 5xFAD Mouse Model of Alzheimer's Disease

Presenter — Meenakshi Bose

Allen PAN (1), Gabriela FARIAS-QUIPILDOR (2, 3), Yong HUANG (1, 3), Minghui WANG (4), Michelle EHRLICH (3), Stephen SALTON (1)

(1) Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, United States, (2) Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, New York, United States, (3) Departments of Neurology, Genetics and Genomic Sciences, and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United States, (4) Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

P198 Exercise Training-Mediated Mitochondrial Modulation in the Alzheimer's Disease Hippocampus

Presenter — Sean Kao

Sean KAO (1, 2), Farhan YOUSAF (3), Shahid ISHAQ (3), Iqbal-Ali SHAH (3), Bor-Tsang WU (4), Shin-Da LEE (3)

(1) Boston Medical Center, Boston, United States, (2) Johns Hopkins University, Baltimore, United States, (3) China Medical University, Taichung, Taiwan, (4) National Taichung University of Science and Technology, Taichung, Taiwan

P229 Preclinical Evaluation of CATA-002, a Novel A β /TfR Bispecific Brain-Shuttled Catalytic Antibody for Enhanced Brain Penetration and Enzymatic A β Degradation in Alzheimer's Disease

Presenter — Yue Liu

Wang BO, Hoag MATTEW, Shan YUXI, Dong JIANBO, Fay NATHAN, Spadoni NICHOLAS, Putrevu SAROJA, Titong ALLISON, Yue LIU

Ab Studio Inc., Hayward, Ca, United States

P249 Next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenter — Sylvain Lehmann

Nicolas PRADEILLES (1), Nadia ANCERIZ (2), Bruno DAUBEUF (2), Pauline LLOVERAS (2), Laurence CHATEL (2), Atizée VIANDIER (2), Adeline LESNIER (2), Eric HATTERER (2), Roman RÖSEMANN (3), Oleg DEMIN JR (4), Dmitry SHCHELOKOV (4), Galina SAYNUKOVA (4), Jean-Philippe COURADE (5)

(1) Laboratoire de Biochimie Protéomique Clinique CHU Montpellier, Hôpital St Eloi, IRMB, Montpellier, France, Montpellier, France, (2) Light Chain Bioscience - Novimmune SA, Geneva, Switzerland, Geneva, Switzerland, (3) Granzer Regulatory Consulting & Services, Muenchen, Germany, Muenchen, Germany, (4) InSysBio CY, Paphos, Cyprus, Paphos, Cyprus, (5) Discoveric bio alpha Ltd., Pfäffikon, Schwyz, Switzerland, Schwyz, Switzerland

P263 QSP platform of Alzheimer's Disease for exploring efficacy of anti-tau immunotherapy bepranemab

Presenter — Tatiana Karelina

Tatiana KARELINA, Dmitry GORDEEV, Olga IVANOVA, Polina MALIUKOVA

InSysBio, Paphos, Cyprus

P299 HET3 mice are a model of brain aging: evidence for dendritic spine loss, proteome perturbations, and spatial learning deficits during aging.

Presenter — Josh Krivinko

Susan ERICKSON (1), Akayla LEWIN (1), Jiaqian LIU (2), Matthew MACDONALD (1), Jason NEWMAN (1), Stacey RIZZO (3), Robert SWEET (1, 4)

(1) Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States, (2) Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, United States, (3) Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, United States, (4) Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh

P334 Neural crest-derived nasal turbinate stem cells enhance the therapeutic efficacy of FDA-approved anti-A β immunotherapy in patient-derived Alzheimer's disease cerebral organoids

Presenter — Sung Won Kim

Jung Yeon LIM (1), Jung Eun LEE (2), Seung Ho YANG (2), Hyun Kook LIM (3)

(1) Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, (2) Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, (3) Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of

P391 Binding profile of lecanemab in brain of patients with early Alzheimer's disease

Presenter — Linda Söderberg

Linda SÖDERBERG, Malin JOHANNESON, Eleni GKANATSIU, Karolina MINTA, Olof ZACHRISSON, Gunilla OSSWALD, Lars LANNFELT, Christer MÖLLER

BioArctic AB, Stockholm, Sweden

P457 Clearing Tau from the Inside Out: TRIM21-Mediated Immunotherapy Against Intracellular Tau Pathology

Presenter — Nemil Bhatt,

Nemil BHATT,, Nikita SHCHANKIN, Twisha CHATTERJEE, Jia Yi LIEW, Balci AHMET, Dhvani PANSURIYA, Rakez KAYED

University of Texas Medical Branch, Galveston, United States

P459 AI-guided protein design combined with multiplexed in vivo screening identifies novel shuttles that efficiently deliver Alzheimer's therapeutics into the CNS with improved pharmacokinetics, biodistribution and target engagement

Presenter — Kimberly Searce-Levie

Kimberly SCEARCE-LEVIE, Alvaro GARCIA, Isabel ALBUJA, Alex GEREW, John AVERA, Glenn HAUK, Noa LIBERMAN-ISAKOV, Marshall CASE, Sharon MCGONIGLE, Brianna UNDA, Fabliha ANAM, Hala HADDAD, Gleb KUZNETSOV, Pierce OGDEN

Manifold Bio, Boston, United States

P618 MPS-AD: Human iPSC-Derived Microphysiological Systems Capture Molecular Heterogeneity and Enable Therapeutic Screening in Alzheimer's Disease

Presenter — Annabel Curle

Annabel CURLE (1, 2), Anna CRAMER (1), Kellianne ALEXANDER (1), Fasih AHSAN (1), Garrett FOGO (1), Courtney BENOIT (1), Richard PEARSE (1), Christina MURATORE (1), Duc DUONG (3), Nicholas SEYFRIED (3), David BENNETT (4), Tracy YOUNG-PEARSE (4)

(1) Mass General Brigham, Boston, United States, (2) Harvard Medical School, Boston, United States, (3) Emory School of Medicine, Atlanta, United States, (4) Rush University Medical Center, Chicago, United States

P630 Exclusive Detection of U-p53AZ in Alzheimer's Disease Compared to Other Neurodegenerative Diseases

Presenter — David Lynch

David LYNCH (1, 2), Sam AGUS (3), Rakez KAYED (1, 2), Madison SAMPLES (1, 2), Yu-Hsiu WANG (4), Rasche MICHAEL (3), Kinnon PAUL (3), Simona PICCIRELLA (5)

(1) Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, United States, (2) Department of Neurology and Neurobiology, University of Texas Medical Branch, (3) Diadem Inc, Palo Alto, United States, (4) Department of Biochemistry and Molecular Biology, UTMB, Galveston, United States, (5) Diadem SpA, Milano, Italy

P660 Trends in Episodic Memory and Cognitive Symptoms in Cognitively Normal APOE2 Homozygotes

Presenter — Aimen Vanood

Aimen VANOOD, Meredith WICKLUND, Donna LOCKE, Blake LANGLAIS, Richard CASELLI, Bryan WOODRUFF

Mayo Clinic, Scottsdale, United States

P21 Power analyses for stepped wedge designs with multivariate continuous outcomes

Presenter — Kendra Plourde

Monica TALJAARD (2), Fan LI (3)

(1) Yale School of Public Health - New Haven (United States), New Haven, United States, (2) Ottawa Hospital Research Institute, Ottawa, Canada, (3) Yale School of Public Health, New Haven, United States

P38 From Initial Enthusiasm to Routine Practice: Temporal Changes in Anti-Amyloid Therapy Uptake and Eligibility in Japan

Presenter — Ryoko Ihara

Ryoko IHARA, Masanori KURIHARA, Keiko HATANNO, Taro BANNAI, Ryosuke SHIMASAKI, Akira HATAKEYAMA, Ko FURUTA, Fumio SUZUKI, Aya TOKUMARU, Kenji ISHII, Atsushi IWATA

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P67 Clinical and operational determinants of amyloid-targeting therapies treatment initiation in early Alzheimer's Disease: A discrete choice experiment

Presenter — Elena Garcia_arcelay

Juan FORTEA (1), Alberto VILLAREJO (3), Raquel SANCHEZ DEL VALLE (4), Neus CANAL (5), Monica SARMIENTO (5), Jorge MAURINO (2), Guillermo GARCIA-RIBAS (6), Gustavo SAPOSNIK (7)

(1) Sant Pau Memory Unit, IR SANT PAU, Hospital Universitario de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona., Barcelona, Spain, (2) Medical Department, Roche Farma, Madrid, Spain, (3) Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain, (4) Department of Neurology, Hospital Clinic, FRCB-IDIBAPS, Universidad de Barcelona, Barcelona, Spain, (5) RWCS, IQVIA Information, Madrid, Spain, (6) Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain, (7) Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Canada. Clinical Outcomes and Decision Neuroscience Unit, Li Ka Shing Institute, University of Toronto, Toronto, Canada

P81 The Effects of Benzgalantamine (ZUNVEYL®) on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in the Treatment of Mild to Moderate Alzheimer's Dementia. RESOLVE: a Phase IV Open-label Study

Presenter — Denis Kay

Michael MCFADDEN, Denis KAY, Carson HARROD, Pavel SVINTOZELSKIY, Andrew WAHLERT, Kurt GRADY

Alpha Cognition Inc., Grapevine, United States

P121 Most Screening-Baseline MMSE Variability Is Individual Noise: Pooled Analysis of 17 Alzheimer's Trials

Presenter — David Miller

Alan KOTT (2), Xingmei WANG (3)

(1) Signant Health, Philadelphia, United States, (2) Signant Health, Prague, Czechia, (3) Signant Health, Blue Bell, United States

P139 Achieving Greater Generalizability in Alzheimer's Clinical Trials through a Multi-sector Committee

Presenter — Christopher Miller

Christine LEE (1), Michelle BRUNO (3), Daphne DELGADO (2), Sam DICKSON (4), Martine MEYER (5), Constantina MIZIS (6), Jonathan TOBIN (7), Charisse WINSTON (8), Michael WEINER (9)

(1) ACHIEVE Expertise, , United States, (2) UsAgainstAlzheimer's, , United States, (3) MB Insights, LLC, , United States, (4) Pentara Corporation, , United States, (5) The Janssen Pharmaceutical Companies of Johnson & Johnson, , United States, (6) Latino Alzheimer's and Memory Disorders Alliance, , United States, (7) Clinical Directors Network, , United States, (8) University of Southern California, , United States, (9) University of California, San Francisco, , United States

P241 From short-term data to long-term trajectories: Statistical modeling framework for predicting multidomain progression in Alzheimer's disease

Presenter — Ryoichi Hanazawa

P309 Responsible Data Sharing at Scale: Building Tiered Open Science Infrastructure for ADRD Clinical Trials

Presenter — Richard Gallardo

Christian NAVARRO (1), Michael DONOHUE (1), Oliver LANGFORD (1), Brenda ARMENTA-COPCA (1), Hongmei QIU (1), Paul NEWHOUSE (2), Paul AISEN (1), Gustavo JIMENEZ-MAGGIORA (1)

(1) University of Southern California, San Diego, United States, (2) Vanderbilt University, Nashville, United States

P420 IMPACT-AD LATAM: A Regional Training Program to Strengthen ADRD Clinical Trial Capacity in Latin America

Presenter — Ma. Florencia Clarens

Maria C. CARRILLO (2), Joshua D. GRILL (3), Rema RAMAN (4), Heather M. SNYDER (2), Lucia CRIVELLI (1), Jorge LLIBRE-GUERRA (5)

(1) Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina, (2) Division of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, United States, (3) Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California, Irvine, United States, (4) Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, (5) Department of Neurology, Washington University in St. Louis, St Louis, United States

P434 Leveraging the NACC Data Platform and ADRC Network Infrastructure to Operationalize CLARiTI: A Model for Multimodal Data Coordination in AD/ADRD Research

Presenter — Heather O'connell

Erin CHIN (2), Shilpa ALLIMATTI (1), Hannah KOENIG (1), Laura MCLEOD (1), Christine MAC DONALD (1), Lindsay CLARK (2), Tatiana FOROUD (3), Gil RABINOVICI (4), Elizabeth MORMINO (5), Sterling JOHNSON (2), Walter KUKULL (6), Sarah BIBER (6, 7)

(1) National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, United States, (2) Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States, (3) Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States, (4) Fein Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, California, United States, (5) Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, United States, (6) Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States, (7) Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States

P486 Advancing Alzheimer's Disease Clinical Trials Through the Critical Path for Alzheimer's Disease Consortium (CPAD)

Presenter — Yashmin Karten

Nicholas HENSCHIED (1), Colleen JACOBSEN (1), Hartmuth KOLB (2), Klaus ROMERO (1), Gregory KLEIN (3), Diane STEPHENSON (1)

(1) Critical Path Institute, Tucson, United States, (2) Enigma Biomedical Group, Knoxville, United States, (3) F. Hoffmann-La Roche Ltd., Basel, Switzerland

P525 Age-Dependent Sensitivity of the MMSE for Detecting Amyloid-Confirmed Alzheimer's Disease

Presenter — Dorothy Macfarlane

Dorothy MACFARLANE, Hale HAILIE, Nolan HADLEY, Vera LUKAS, Poplyk SOPHIA, Namaky NAUDER

Adams Clinical, Watertown, United States

P569 Design considerations of a phase II multi-site randomized controlled trial of Harmony Dementia Care: a sensory-based intervention for people with Alzheimer's disease and related dementias

Presenter — Elizabeth K. Rhodus

David S. GELDMACHER (2), Rema RAMAN (3), Michael DONOHUE (3), Laura HENLEY (1), Clarissa BENZARTI (1), April STAUFFER (1), Nancy WOLFF (1), Kennedy WALCOTT-GEORGE (1), Susan WESTNEAT (1), Carolyn BAUM (4), Paul AISEN (3)

(1) University of Kentucky, Lexington, United States, (2) University of Alabama at Birmingham, Birmingham, United States, (3) Alzheimer's Therapeutic Research Institute, San Diego, United States, (4) Washington University in St. Louis, St. Louis, United States

P592 Listening Before Recruiting: Community Listening Sessions to Improve Alzheimer's Research Engagement

Presenter — Sonia Simons

Marilyn WILSON (1), B. Joy SNIDER (1), David CARR (1), Maryanna MILANEZ (2), Emily DUGAN (1), Jordan KULAGE (1)

(1) Washington University School of Medicine, St. Louis, United States, (2) Global Alzheimer's Platform Foundation, Inc., Chicago, United States

P602 The Financial and Societal Impact of Compromised Data Integrity in AD Trials and the Importance of Early Detection and Monitoring

Presenter — Maycee A. Robison

Maycee A. ROBISON, Garrett B. DUNCAN, John WHETTEN, Mitchell B. WASSOM, Samuel P. DICKSON, Suzanne B. HENDRIX

Pentara Corporation, Millcreek, United States

P717 Clinical Trials Should Run Multi-Omic Foundation Models in the Loop

Presenter — Arvid Gollwitzer

Arvid GOLLWITZER (1, 2), Adrian NORIEGA DE LA COLINA (1, 2, 3), Li-Huei TSAI (1, 4), Miia KIVIPELTO (5, 6), Giovanni TRAVERSO (1, 2, 7)

(1) Broad Institute of MIT and Harvard, Cambridge, United States, (2) Massachusetts Institute of Technology, Cambridge, United States, (3) Brigham and Women's Hospital, Boston, United States, (4) The Picower Institute for Learning and Memory, Cambridge, United States, (5) FINGERS Brain Health Institute, Stockholm, Sweden, (6) Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, (7) Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States

COGNITIVE AND FUNCTIONAL OUTCOMES (29)

P28 Real-World Effectiveness of Lecanemab in Japanese Patients with Alzheimer's Disease: A Single-Center Study

Presenter — Ryosuke Shimasaki

Ryosuke SHIMASAKI (1, 2, 3), Ryoko IHARA (1, 2), Masanori KURIHARA (1, 2), Kenichiro SATO (1, 2, 4), Taro BANNAI (1), Keiko HATANNO (1), Fumio SUZUKI (5), Aya TOKUMARU (5), Kenji ISHII (6, 2), Sumito OGAWA (3), Atsushi IWATA (1, 2)

(1) Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (2) Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (3) Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, (4) Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan, (5) Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, (6) Research Team of Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P34 Digital Cognitive Signatures of Biomarker-Defined Preclinical Alzheimer's Disease

Presenter — Casey Vanderlip

Casey VANDERLIP (1, 2), Karra HARRINGTON (2), Paul MARUFF (2), Pam VENTOLA (2)

(1) UC Irvine, Irvine, United States, (2) Cogstate Ltd, Melbourne, Australia

P74 High-Frequency Monitoring of Cognitive and Biomarker Changes in Healthy Aging Over One Year

Presenter — Michelle Budman

Phyllis TAMEILAU (1), Alexandra N. TRELLE (1), S. SUBBULAKSHMI (2), Jintao SHENG (2, 3), Tran T. NGUYEN (4), Divya CHANNAPPA (1), Gayle DEUTSCH (2), Holden T MAECKER (5), Sharon SHA (1), Tony WYSS-CORAY (1, 3), Anthony D. WAGNER (2), Christina B. YOUNG (6, 7), Joseph R. WINER (8), Elizabeth C. MORMINO (1, 9)

(1) Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, United States, (2) Department of Psychology, Stanford University, Palo Alto, United States, (3) Phil and Penny Knight Initiative for Brain Resilience, Palo Alto, United States, (4) Institute for Immunity, Transplantation, and Infection Operations, Stanford University, Palo Alto, United States, (5) Department of Microbiology and Immunology, Stanford University, Palo Alto, United States, (6) Department of Radiology, UC Davis, Davis, United States, (7) Department of Neurology, UC Davis, Davis, United States, (8) Sutter Health Research Institute, San Francisco, United States, (9) Wu Tsai Neurosciences Institute, Palo Alto, United States

P76 Treatment-Related Amyloid Clearance with Lecanemab at 1-year : Stage-Dependent Response in a Real-World Cohort

Presenter — Jee Hyang Jeong

Geon Ha KIM (2)

(1) Ewha Womans University Seoul Hospital, Seoul, Korea, Republic of, (2) Ewha Womans University Mokdong Hospital (Korea, Republic of), Seoul, Korea, Republic of

P130 Comparison-Based Subjective Cognitive Decline Predicts Objective Cognition in APOE ϵ 4 Non-Carriers

Presenter — Jee Wook Kim

Hye Ji CHOI (1), Shin Gyeom KIM (2)

(1) Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, (2) Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of

P144 Real-World Lecanemab Treatment in Early Alzheimer's Disease: A Retrospective Case Series from a Geriatric Medicine Clinical Practice

Presenter — Margarita Reyes

Margarita REYES, Mary Maxine Zapata REYES

Office of Dr Reyes, Bristol, United States

P201 ADAS-Cog 11 vs 13 in early Alzheimer's disease: sensitivity to longitudinal change

Presenter — Daema Pina Delgado

Catarina CUNHA (1), Matt WELCH (2), Zsolt TERNEI (3), Selam NEGASH (2), Chris RANDOLPH (2)

(1) Clario, part of Thermo Fisher Scientific, Coimbra, Portugal, (2) Clario, part of Thermo Fisher Scientific, Philadelphia, United States, (3) Clario, part of Thermo Fisher Scientific, Budapest, Hungary

P213 A Retrospective, Case-Series Analysis of Lecanemab Treatment in Individuals with Early Alzheimer's at a Colorado Neurological Clinic

Presenter — Adam Wolff

Porter Adventist Hospital, Colorado Neurological Clinic, Denver, United States

P248 Experience, Not Education, Drives Rater Performance on the Clinical Dementia Rating Scale

Presenter — Dorothee Schoemaker

Dorothee SCHOEMAKER, Danielle DIGREGORIO, Selam NEGASH, Cong LIU, Chris RANDOLPH

Clario, part of Thermo Fisher Scientific, , United States

P283 Increasing granularity in the Clinical Dementia Rating: Does a 0.25 Memory box score signal faster cognitive decline?

Presenter — Mark A. Dubbelman

Mark A. DUBBELMAN (1, 2), Vivienne LUBBAT (2), Hairin KIM (1, 2), Lex R. MINTO (1, 2), Dorene M. RENTZ (1, 2), Rachel F. BUCKLEY (1, 2), Reisa A. SPERLING (1, 2), Gad A. MARSHALL (1, 2), Rebecca E. AMARIGLIO (1, 2), Kathryn V. PAPP (1, 2)

(1) Center for Alzheimer Research & Treatment, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, United States, (2) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States

P284 Understanding NPI-C Rating Errors in AD Psychosis Trials: A Multi-Study Analysis of Hallucination and Delusion Domain Flags

Presenter — Amanda Aedo

Amanda AEDO, Gila BARBATI, Andrei IACOB, Sayaka MACHIZAWA, Erica APPLEMAN

Signant Health, Coral Springs, United States

P289 Comparative analysis of lexical and acoustic speech biomarkers in mild cognitive impairment due to Lewy bodies and Alzheimer's disease

Presenter — Min Seok Baek

Min Seok BAEK (1, 2), Sung-Woo KIM (1), Han-Kyeol KIM (1), Mark LIBERMAN (3), Sunghye CHO (4)

(1) Department of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, (2) Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, United States, (3) Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, Korea, Republic of, (4) Department of Communication Sciences and Disorders, University of Cincinnati, Cincinnati, Korea, Republic of

P321 Associations of frailty, cognition and amyloid status in preclinical Alzheimer's disease in prerandomization data from the AHEAD 3-45 study

Presenter — Paul Yates

Andrew HUYNH (1, 2, 3), David WARD (4), Scott WRIGLEY (1), Courtney SHELTON (1), Sanka AMADORU (1, 2), Michael WOODWARD (1, 2), Louise BURRELL (2), Paul YATES (1, 5)

(1) Department of Geriatric Medicine, Austin Health, Melbourne, Australia, (2) Department of Medicine, University of Melbourne, Melbourne, Australia, (3) Alzheimer's Research Australia, Melbourne, Australia, (4) Frazer Institute, Faculty of Health, Medicine & Behavioural Sciences, University of Queensland, Brisbane, Australia, (5) Department of Medicine, Melbourne, Australia

P336 Real-World Long-Term Persistence and Early Subcutaneous Maintenance Utilization of Lecanemab in the United States

Presenter — Michael Rosenbloom

Diana BRIXNER (1), Chenyue ZHAO (2), Hideki TOYOSAKI (2), Feride FRECH (2)

(1) Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, United States, (2) Eisai Inc., Nutley, United States, (3) Memory and Brain Wellness Center, University of Washington, Seattle, United States

P354 Real-World Patient-Reported Outcomes with Subcutaneous Lecanemab Treatment in Early Alzheimer's Disease in the United States: A Case Series

Presenter — Victor Faradji

Victor FARADJI, Jaziel RODRIGUEZ

First Choice Neurology and Visionary Investigators Network (VIN), Miami, United States

P389 Estimating progression from MCI to dementia with a MoCA clock

Presenter — Willem Huijbers

Murray GILLIES (1), Ziad NASREDDINE (1), Suzanne SCHINDLER (2), Kellen PETERSEN (2)

(1) MoCA Cognition, Montreal, Canada, (2) Department of Neurology, Washington University in St. Louis, St. Louis, United States

P414 Virtual Reality Measures of Everyday Function and Cognition Characterizes the Risk of Early-Stage Alzheimer's Disease

Presenter — James Galvin

James GALVIN, Mustafa SHUQAIR

University of Miami Miller School of Medicine, Boca Raton, United States

P484 Advancing Personalized Outcome Assessment in Frontotemporal Dementia: A Standardized Goal Inventory for Goal Attainment Scaling (GAS) in Clinical Trials

Presenter — Chere Chapman

Gunes SEVINC (1), Kaitlin CASALETTO (3), Howie ROSEN (3), Kenneth ROCKWOOD (4)

(1) Ardea Outcomes, Vancouver, Canada, (2) Ardea Outcomes, Halifax, Canada, (3) University of California, San Francisco, San Francisco, Canada, (4) University of California, San Francisco, Halifax, Canada

P543 A Harmonized Multi-Cohort Evaluation of SOMI Stages for Predicting Cognitive Impairment

Presenter — Priyanka Kumari

Priyanka KUMARI (1), Richard B. LIPTON (1, 2, 3), Cuiling WANG (3), Ellen GROBER (1)

(1) Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States, (2) Montefiore Medical Center, Bronx, NY, United States, (3) Department of Epidemiology & Population Health, Bronx, NY, United States

P547 Real-World Cognitive, Safety and Biomarker Outcomes Among Patients Receiving Anti-Amyloid Monoclonal Antibodies in ALZ-NET

Presenter — Gil Rabinovici

Alireza ATRI (2), Kirk DAFFNER (3), Constantine GATSONIS (4), Oscar LOPEZ (5), Anton PORSTEINSSON (6), Katherine POSSIN (1), Stephen SALLOWAY (7), Mary SANO (8), Christopher WHITLOW (9), Charloes WINDON (1), Michael RAFII (10), Maria CARRILLO (11)

(1) Fein Memory and Aging Center, Depts. of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, United States, (2) Banner Alzheimer's & Research Institutes, Banner Research/Banner Health, Peoria, United States, (3) Harvard School of Medicine, Boston, United States, (4) Brown School of Public Health, Providence, United States, (5) University of Pittsburgh School of Medicine, Pittsburgh, United States, (6) University of Rochester School of Medicine, Rochester, United States, (7) Butler Hospital / Warren Alpert Medical School of Brown University, Providence, United States, (8) Mt Sinai School of Medicine, New York, United States, (9) Yale University / American College of Radiology, New Haven, United States, (10) Keck School of Medicine, University of Southern California, San Diego, United States, (11) Alzheimer's Association, Chicago, United States

P579 Technical and Real-World Validation of the Digital Clock and Recall: A Scalable Cognitive Screener for Primary Care and Clinical Trial Enrichment

Presenter — Ali Jannati

Claudio TORO-SEREY (1), Karl THOMPSON (1), Daniel SCHULMAN (1), Olivia JACKS (1), Connor HIGGINS (1), Alvaro PASCUAL-LEONE (1, 2), Sean TOBYNE (1)

(1) *Linus Health, Boston, United States*, (2) *Hebrew SeniorLife - Harvard Medical School, Boston, United States*

P582 A Digital Clock and Recall (DCR)-First Clinical Workflow Substantially Increases Dementia Case-Finding in Primary Care

Presenter — Ali Jannati

Claudio TORO-SEREY (1), Connor HIGGINS (1), John SHOWALTER (1), David BATES (1), Alvaro PASCUAL-LEONE (1, 2), Sean TOBYNE (1)

(1) *Linus Health, Boston, United States*, (2) *Hebrew SeniorLife - Harvard Medical School*

P599 Measuring meaningful benefits across cultures in AD trials: feasibility, applicability, and user acceptability of the ePSOM tool in Japanese memory clinics

Presenter — Stina Saunders

Stina SAUNDERS (1, 2), Yuki TAKEDA (3), Hisatomo KOWA (4), Atsushi IWATA (5), Norio CHIHARA (6), Himanshi MALIK (1), Ali JANNATI (1, 7), Claudio TORO-SEREY (1), Sean TOBYNE (1), Ricky KURZMAN (8), Yosuke NAKAMURA (9), Jo VANDERCAPPELLEN (10), Álvaro PASCUAL-LEONE (1, 7, 11)

(1) *Linus Health, Boston, United States*, (2) *University of Edinburgh, Edinburgh, United Kingdom*, (3) *Kobe University, Graduate School of Medicine, Division of Neurology, Kobe, Japan*, (4) *Kobe University, Graduate School of Medicine, Department of Health Sciences, Suma-ku, Kobe, Japan*, (5) *Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan*, (6) *Kobe University, Graduate School of Medicine, Division of Neurology, Tokyo, Japan*, (7) *Department of Neurology, Harvard Medical School, Boston, United States*, (8) *Eisai Inc., Nutley, United States*, (9) *Eisai Co Ltd, Tokyo, Japan*, (10) *Eisai Pharma AG, Zurich, Switzerland*, (11) *Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States*

P638 Real-World Effectiveness, Safety, and Patient Experience of Lecanemab in the United States: A Systematic Literature Review

Presenter — Gregory Jicha

Chenyue ZHAO (2), Dominic IGBELINA (3), James FRAMPTON (3), Henry OGDEN (3), Feride FRECH (2), Hideki TOYOSAKI (2), Joanna CAMPBELL (3), Liana APOSTOLOVA (4)

(1) *University of Kentucky College of Medicine, Lexington, United States*, (2) *Eisai Inc., Nutley, United States*, (3) *Thermo Fisher Scientific Inc., Waltham, United States*, (4) *Indiana University School of Medicine, Indianapolis, United States*

P641 Effects of regional tau accumulation on visual discrimination behaviors in clinically unimpaired older adults

Presenter — Dhruv Kapadia

Lucah GUERRA (1), Isha SAI (1), Tyler BONNEN (2), Anthony WAGNER (1), Elizabeth MORMINO (1), Alexandra TRELLE (1)

(1) *Stanford University, Stanford, United States*, (2) *University of Pennsylvania, Philadelphia, United States*

P645 Lecanemab Treatment in a New England Alzheimer's Disease Center: Real-World Outcomes From a Single-Center, Retrospective Case Series

Presenter — Salvatore Napoli

Salvatore NAPOLI, Rachel O' DONNELL, Lauren NASSR, Emily MAIZE

Alzheimer's Neurology and Infusion Centers of New England, Foxboro, United States

P648 Streamlining the Alzheimer's Disease Diagnostic Journey through Primary Care: Real-World Insights from the Better DX Study

Presenter — Rhonna Shatz

Katherine SCHMIDT (1), Jinda BOWERMAN (1), Jackson HEARN (1), Feride FRECH (2), Bryan COBB (2), Courtney ADAMS (2), Yosuke NAKAMURA (2), Rifky TKATCH (2), Hideki TOYOSAKI (2)

(1) *University of Cincinnati, Cincinnati, United States*, (2) *Eisai Inc., Nutley, United States*

P671 Unawareness of medication self-administration errors as a clinical outcome and marker of cognitive decline.

Presenter — A.m. Barrett

Honghuang LIN (1), Joanne MURABITO (2), Emily MULLER (1)

(1) UMass Chan Medical School, Worcester, United States, (2) UMass Chan Medical School, Boston, United States

P707 Switching from Oral Donepezil to a Twice-weekly Korean Transdermal Donepezil Patch in Dementia with Parkinson's Disease

Presenter — Mee Y Park

Jean Seo AN (2)

(1) Neurology, Yeungnam University Medical Center, Daegu, Korea, Republic of, (2) Biological Sciences, University of Illinois Chicago (UIC), Chicago, IL, Chicago, United States

DIGITAL ENDPOINTS, REMOTE MONITORING & CONNECTED HEALTH TOOLS (20)

P31 The Person, Not the Device: Evidence from Ten Years of In-Home Remote Monitoring Research in Dementia

Presenter — Ramin Nilforooshan

Ramin NILFOROOSHAN (1, 2), Chloe WALSH (1, 3), Sai-Bo CHEUNG (1)

(1) Surrey and Borders Partnership NHS Foundation Trust, Chertsey, United Kingdom, (2) University of Surrey, Guildford, United Kingdom, (3) Imperial College London, London, United Kingdom

P37 Tracking Cognitive Change in Mild Cognitive Impairment Using Repeated Speech-Based Digital Cognitive Assessments: Comparison with the Clinical Dementia Rating Scale

Presenter — Alexandra König

Johannes TRÖGER (1), Elisa MALLICK (1), Alison BUICK (1), Mathias BÄHR (2), Emrah DÜZEL (3), Björn FALKENBURGER (4), Gabor PETZOLD (5), Josef PILLAR (6), Annika SPOTTKE (5), Stefan TEIPEL (7), Michael WAGNER (5), Jens WILTFANG (2), Inga ZERR (2), Stefanie KÖHLER (7)

(1) ki elements GmbH, Saarbrücken, Germany, (2) German Center for Neurodegenerative Diseases DZNE, Göttingen, Germany, (3) German Center for Neurodegenerative Diseases DZNE, Magdeburg, Germany, (4) German Center for Neurodegenerative Diseases DZNE, Dresden, Germany, (5) German Center for Neurodegenerative Diseases DZNE, Bonn, Germany, (6) German Center for Neurodegenerative Diseases DZNE, Berlin, Germany, (7) German Center for Neurodegenerative Diseases DZNE, Rostock, Germany

P192 Automated verbal fluency as a digital cognitive biomarker in progressive supranuclear palsy: a longitudinal study

Presenter — Charlie Weige Zhao

Jesse WANG (1), Ilkay POTTER (2), Ram MISHRA (2), Kyurim KANG (3), Tejas PAWAR (2), Rylee COLE (2), Ashkan VAZIRI (2), Alexander PANTELYAT (3), Anne-Marie WILLS (1)

(1) Mass General Brigham, Boston, United States, (2) Biosensics LLC, Newton, United States, (3) Johns Hopkins University, Baltimore, United States

P195 Longitudinal digital speech assessment in progressive supranuclear palsy

Presenter — Charlie Weige Zhao

Kyurim KANG (1), Ilkay POTTER (2), Ram MISHRA (2), Rylee COLE (2), Tejas PAWAR (2), Antje MEFFERD (4), Michael DE RIESTHAL (5), Ashkan VAZIRI (2), Anne-Marie WILLS (3), Alexander PANTELYAT (3)

(1) Johns Hopkins University, Baltimore, United States, (2) Biosensics LLC, Newton, United States, (3) Mass General Brigham, Boston, United States, (4) Vanderbilt University Medical Center, Nashville, United States, (5) Vanderbilt University, Nashville, United States

P211 Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, Community Partners and Embedded Clinical Trial Recruitment

Presenter — Gregory Sahagian

The Neurology Center of Southern California, Carlsbad, United States

P218 A/B-test results of XpressO-Mix: a remote cognitive prescreener that mitigates practice effects

Presenter — Willem Huijbers

Hans-Aloys WISCHMANN (2), Murray GILLIES (1), Ziad NASREDDINE (1)

(1) MoCA Cognition, Montreal, Canada, (2) Charité, Berlin, Germany

P281 Ensuring Demographic Equity: Evaluating the SB-C Speech-Based Cognitive Assessment Across Ethnic Groups in US

Presenter — Alexandra König

Johannes TRÖGER, Louisa SCHWED, Simona SCHÄFER, Alison BUICK, Nicklas LINZ, Alexandra KÖNIG

ki elements GmbH, Saarbrücken, Germany

P288 Promoting dementia research participation in high-risk communities – co-creating a Research Ambassador Program.

Presenter — Sarah Walter

Joe COSTELLO (2), Cynthia HULING HUMMEL (3), Paul AISEN (1), Colin CHANDLER (4), Leah MACADEN (5)

(1) Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, (2) Alzheimer's Clinical Trials Consortium, Research Ambassador Community Collective - San Diego (United States), San Diego, United States, (3) Alzheimer's Clinical Trials Consortium, Research Ambassador Community Collective, San Diego, United States, (4) School of Health in Social Science, University of Edinburgh, Edinburgh, United Kingdom, (5) 4. Nursing Studies, School of Health in Social Science, University of Edinburgh, Edinburgh, United Kingdom

P397 Smartphone-based User-adaptive Assessment of Cognitive Functions in Patients with Mild Cognitive Impairment

Presenter — Shibeshih Belachew

Antonio RODRÍGUEZ-ROMERO (1), Katarzyna KITA (1), Alexa BURK (2), Emmanuel BARTHOLOMÉ (1), Claudia MAZZÀ (1), Carlos LUQUE (1), Óscar REYES (1), Corrado BERNASCONI (1), Rhoda AU (2)

(1) Indivi AG, Basel, Switzerland, (2) Boston University Chobanian & Avedisian School of Medicine, Boston, United States

P400 Improving Early Detection of Cognitive Impairment with Cognivue Clarity Across Diverse Clinical Settings: Accounting for Age, Education and Race Differences in Performance

Presenter — James Galvin

Paul ESTES (2), Heather HARRIS (2), Lun-Ching CHANG (3)

(1) University of Miami Miller School of Medicine, Boca Raton, United States, (2) Cognivue, Inc, Victor, United States, (3) Florida Atlantic University, Boca Raton, United States

P401 Remote Odor Percept Identification as a Scalable Marker of Alzheimer's Disease

Presenter — Benoît Jobin

Benoît JOBIN, Colin MAGDAMO, Hengbin ZHANG, Beyzanur ERGUN, Reineke SEAN, Dhillia-Albers ALEFIYA, Albers MARK

Mass General Brigham/Harvard Medical School, Boston, United States

P432 Refer-MCI: Enriching Referrals of Patients to Memory Clinics for Mild Cognitive Impairment (MCI)

Presenter — Emrah Duezel

Emrah DUEZEL (1, 2, 3), Jochen René THYRIAN (4), Vanessa KURTH (5), Nadine DIERSCH (3), Anne BOEHLLEN (6), Hannes VOSSFELDT (3), David BERRON (1, 3), Frank JESSEN (6, 7), Annika SPOTKE (6), Stefan TEIPEL (8)

(1) German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, (2) Otto-von-Guericke University, Institute of Cognitive Neurology and Dementia Research (IKND), Magdeburg, Germany, (3) neotiv GmbH, Magdeburg, Germany, (4) German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany, (5) Lilly Germany, Bad Homburg, Germany, (6) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, (7) University of Cologne, , Cologne, Germany, (8) German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany

P470 Evaluation of the Effects of Donepezil on Cognition and Daily Function in Amyloid-Positive MCI: An Exploratory Randomized Study Using Eye-Tracking Metrics

Presenter — Ko Woon Kim

Ko Woon KIM, Byung-Soo SHIN

Jeonbuk National University Medical School and Hospital - Jeonju (United States), Jeonju, Korea, Republic of

P496 Maximizing Signal in Early AD: How Digital Assessments Outperform the CDR-SB and ADAS-Cog

Presenter — Katelyn Miller

Katelyn MILLER, Samuel DICKSON, Suzanne HENDRIX

Pentara Corporation, Millcreek, Ut, United States

P499 Understanding Cognitive Impairment Through Analysis of Process Metrics Derived from the Digital Assessment of Cognition

Presenter — Tanya Talkar

Connor HIGGINS (1), Ali JANNATI (1), David LIBON (1, 2, 3), Rod SWENSON (1, 4), Sean TOBYNE (1)

(1) *Linus Health, Boston, United States*, (2) *Department of Geriatrics and Gerontology, New Jersey Institute for Successful Aging, Rowan University-School of Osteopathic Medicine, Glassboro, United States*, (3) *Department of Psychology, Rowan University, Glassboro, United States*, (4) *University of North Dakota School of Medicine and Health Sciences, Grand Forks, United States*

P520 Cognitive Benefit from the Structured Lifestyle Intervention in U.S. POINTER Replicated and Extended with Digital Cognitive Outcomes

Presenter — Kathryn Papp

Sarah FARIAS (2), Sarah EVANS (3), Magdalene HARKI (4), Joni EVANS (3), Athene LEE (5), Bonnie SACHS (6), Christy TANGNEY (7), Maria CARRILLO (8), Katie GARCIA (3), Amber THRO (6), Iris LENG (6), Kristin IJEH (9), Mark ESPELAND (6), Laura BAKER (6)

(1) *Mass General Brigham*, (2) *UCDavis*, (3) *Advocate Health*, (4) *AAH*, (5) *Brown University*, (6) *Wake Forest*, (7) *Rush*, (8) *Alzheimer Association*, (9) *BCM*

P577 A Novel use of Eye-Tracking and Digital Ink to Reveal, Identify and Quantify Natural Learning Strategies in Real-Time: A First Look at the Moment When Memory Associations are Made

Presenter — Dana Penney

Nhung VAN (2), Junji QU (2), Vineet SARAVANAN (2), Jessica XU (2), Maria Ascanio ALINO (2), Fang Lu FU (3), Talia L. ROBINSON (4), Randall DAVIS (2)

(1) *Lahey Hospital and Medical, Burlington, United States*, (2) *MIT, Cambridge, United States*, (3) *Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States*, (4) *Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, Boston, United States*

P578 Noise-cancellation variability as a source of longitudinal drift in speech-based digital endpoints for Alzheimer's disease trials

Presenter — Chiang Lisa

Adrian ORTIZ, Chiang LISA

Cephalgo, Strasbourg, France

P704 Associations between Alzheimer's disease biomarkers and multiday digital cognitive performance in older adults at elevated vascular risk

Presenter — Lex Minto

Lex MINTO (1, 2), Hairin KIM (1, 2), Mark DUBBELMAN (1, 2), Daniel SOBERANES (1), Vivienne LUBBAT (1), Laura BAKER (3), Mark ESPELAND (3), Susan LANDAU (4), Rebecca AMARIGLIO (1, 2), Kathryn PAPP (1, 2)

(1) *Mass General Brigham, Boston, United States*, (2) *Harvard Medical School, Boston, United States*, (3) *Wake Forest University School of Medicine, Winston-Salem, United States*, (4) *University of California, Berkeley, Berkeley, United States*

P726 SpeechDx: Advancing Prognostic Speech Markers for Alzheimer's Disease

Presenter — Melissa Lee

Shirine MOUKALED (1), Andréa Lessa BENEDET (2), Henrik ZETTERBERG (2), Stephan MEYLAN (1, 3), Jerica REEDER (1), Speech Dx THE SPEECHDX CONSORTIUM (1), Aishwarya SUKUMAR (4), Laura NISENBAUM (1), Lampros KOURTIS (1, 4)

(1) *Alzheimer's Drug Discovery Foundation, New York, United States*, (2) *University of Gothenburg, Mölndal, Sweden*, (3) *Surprisal B.V., Amsterdam, The Netherlands*, (4) *Gates Ventures, Kirkland, United States*
